

Preventive Vaccination Uptake by Self-Reported Sexual Orientation Among U.S. Adults: Evidence from IPUMS NHIS 2021–2024.

Abstract

This capstone examines preventive vaccination uptake by self-reported sexual orientation among U.S. adults using pooled IPUMS National Health Interview Survey data from 2021–2024. The study compares heterosexual, gay/lesbian, and bisexual adults across HPV, Hepatitis A, Hepatitis B, influenza, tetanus/Td, COVID-19, shingles, and pneumococcal vaccination. Survey-weighted logistic regression models are used to estimate unadjusted and adjusted average marginal effects. Results show that vaccination uptake varies meaningfully by vaccine type and sexual-orientation subgroup. In the adjusted models, gay/lesbian adults have higher vaccination probabilities than heterosexual adults for several vaccines, with especially large differences for Hepatitis B, shingles, COVID-19, and Hepatitis A vaccination. Bisexual adults show a more vaccine-specific pattern, with the largest adjusted difference observed for HPV vaccination. Gender-stratified models further suggest that adjusted sexual-orientation differences are more consistent among males than females, particularly among gay/lesbian males. This study provides recent national evidence on sexual-orientation differences in routine adult vaccination in the post-COVID period and highlights the importance of continued SOGI data collection, subgroup-specific analysis, and targeted adult vaccination strategies.

1. Introduction

Vaccination is widely recognized as one of the most efficient and effective preventive health investments. Vaccines reduce the risk of illness, hospitalization, disability, and death, while also lowering medical spending, caregiver burden, and productivity losses (Ozawa et al., 2016; White, 2019; Blanchet Zumofen et al., 2022). Recent evidence from COVID-19 vaccination further demonstrates the large economic return and public health value of vaccines (Padula et al., 2021; Kirson et al., 2022; Freedman et al., 2023). Because vaccination can reduce disease transmission beyond the vaccinated individual, it generates positive externalities through broader spillover benefits to society (Arrow, 1963; Carpenter & Lawler, 2019). These private and social benefits provide an economic rationale for public vaccination programs and policies aimed at increasing coverage.

Despite these benefits, many adults remain unvaccinated for routine immunization. The CDC report from the 2022 National Health Interview Survey (NHIS) shows that only 22.8 percent of adults were up to date on all age-appropriate vaccines. Increasing immunization coverage is a

core national objective highlighted by Healthy People 2030, which explicitly links higher vaccination rates to the long-term goal of mitigating infectious disease throughout the lifespan.

A large body of literature has examined how adult vaccination differs by demographic factors such as race, ethnicity, and gender. Racial and ethnic differences have been documented across several adult vaccines, with Black and Hispanic adults often reporting lower coverage than White adults (Rangel et al., 2005; Lu et al., 2015; Granade et al., 2022; Peña et al., 2023). Gender differences have also been observed, although the direction of the difference varies across vaccines and measures of uptake or acceptance (Kini et al., 2022; Park & Kim, 2024). Together, this literature shows that subgroup differences are an important part of adult vaccination research.

Compared with race, ethnicity, and gender, sexual orientation has received less attention as a dimension of adult vaccination research, especially in health economics. This gap is partly due to limited data availability, inconsistent measurement of sexual orientation, and small subgroup sample sizes. These limitations make it difficult to study sexual minority adults separately by subgroup. Addressing this data gap is consistent with Healthy People 2030's emphasis on improving the health, safety, and overall well-being of LGBT individuals and underscores the need for better population-level data to inform effective health promotion strategies for this community.

There are several reasons to expect vaccination uptake to differ by sexual orientation. First, sexual minority adults may face different health risks and vaccine-related recommendations for some diseases. Second, sexual minority adults may experience barriers to healthcare, including stigma, discrimination, lack of culturally competent care, financial barriers, and lower trust in healthcare settings. Third, sexual minority adults may differ from heterosexual adults in socioeconomic status, employment, insurance coverage, health behaviors, and health status, all of which may influence access to preventive services.

This capstone uses pooled 2011–2018 IPUMS NHIS data to analyze preventive vaccination uptake by sexual orientation among U.S. adults. Comparing heterosexual, gay/lesbian, and bisexual adults, the study examines HPV, hepatitis A, hepatitis B, influenza, tetanus/Td, COVID-19, shingles, and pneumococcal vaccination coverage. It assesses whether orientation-based differences persist after adjusting for demographic, socioeconomic, health, and healthcare-access factors. Srivastav et al. (2019) provides the closest prior evidence on adult vaccination uptake by sexual orientation. This study uses a similar empirical approach but extends the literature by analyzing more recent post-COVID NHIS data and a broader set of adult vaccines. Given that recent vaccination literature often emphasizes COVID-19, this study provides updated, nationally representative evidence on routine and preventive adult vaccination differences by sexual orientation.

2. Literature Review

2.1. Adult Vaccination Behavior

Vaccination uptake is shaped by both Socio-economic and access-related factors. Socioeconomic factors such as education, family background, income, and employment are important because they affect both health knowledge and the practical ability to obtain preventive care (Lleras-Muney, 2005; Cutler & Lleras-Muney, 2010; Epstein et al., 2009).

Adults may also face barriers related to healthcare access and insurance coverage which impact vaccination. Ellis and Manning (2007) used immunization as an example of preventive care to show that insurance coverage matters for prevention because individuals may underuse services that reduce future illness and medical costs. Similarly, the CDC's 2022 adult vaccination coverage summary reported lower coverage among adults without health insurance or a usual place for healthcare. Therefore, the likelihood of receiving vaccines by adults is influenced by multiple factors.

2.2. Socioeconomic and Health Dynamics of Sexual Minority Adults

Economic research shows that sexual minority adults differ from heterosexual adults in earnings, occupational sorting, and economic security. Gay men are often found to earn less than comparable heterosexual men, while lesbian women sometimes earn more than heterosexual women, suggesting that labor-market outcomes vary by both sexual orientation and gender (Antecol et al., 2008; Badgett et al., 2021; Drydakis, 2019; Sabia 2014). More broadly, Badgett et al. (2021, 2024) emphasize that LGBTQ+ populations differ from heterosexual and cisgender populations across human capital, family formation, labor-market outcomes, and economic security.

These labor-market differences are relevant to vaccination because income, employment stability, and employer-sponsored insurance may influence whether adults have affordable and regular access to preventive healthcare. Carpenter et al. (2020) show that the Affordable Care Act dependent coverage mandate increased health insurance coverage among young adults in same-sex couples, especially men ages 21–25, largely through employer-sponsored insurance. This evidence is relevant to the present study because insurance coverage is an important access pathway through which sexual minority adults may receive preventive care, including recommended adult vaccines.

Sexual minority adults also differ from heterosexual adults in health status, healthcare experiences, and exposure to stigma. Prior research documents higher burdens of poor mental health, substance use, HIV infection, smoking, heavy alcohol use, and other risk factors among sexual minority adults compared with heterosexual adults (Boehmer, 2002; Bostwick et al., 2010; Conron et al., 2010; Blosnich et al., 2014; Cochran et al., 2013; Gonzales et al., 2016; Gonzales & Henning-Smith, 2017; Gorman et al., 2015; Hatzenbuehler et al., 2008; Meyer,

1995). These patterns are not uniform across sexual minority subgroups. Pharr et al. (2019) find that bisexual adults, particularly bisexual women, often report poorer self-rated health, higher depression, smoking, heavy drinking, and greater economic insecurity compared with straight women and gay/lesbian adults.

Healthcare access and provider experience may further shape preventive service use among sexual minority adults. Studies show that sexual minorities are more likely to be uninsured and to delay or forgo medical care because of financial cost (Buchmueller & Carpenter, 2010; Dahlhamer et al., 2016; Gonzales & Blewett, 2014; Heck et al., 2006; Ponce et al., 2010). In addition, sexual and gender minorities may experience barriers in healthcare settings, including unequal treatment, lack of appropriate care, poor provider communication, lack of culturally competent care, and cis-heteronormative assumptions (Silva & Costa, 2020; Heer et al., 2023). Nguyen et al. (2024) further show that sexual and gender minority adults report higher levels of social risk factors, including financial strain and transportation barriers, which may affect access to preventive care. These barriers are relevant to vaccination because adult vaccine uptake often depends on access to healthcare, provider interaction, and the ability to obtain preventive services.

2.3. Vaccination Among Sexual Minority Adults

Vaccination may be especially relevant for some sexual minority subgroups and vaccine types. Gay, bisexual, and other men who have sex with men are at elevated risk for some vaccine-preventable diseases, including HPV, hepatitis A, and hepatitis B (CDC, 2024; HHS, 2020; Immunize.org, 2025; Meites et al., 2022; NICE, 2022). This concern fits within broader evidence that sexual and gender minority populations have been disproportionately affected by HIV, sexually transmitted infections, and STI-related cancers (Blondeel et al., 2016). Sexual orientation may therefore be associated with vaccination uptake through competing mechanisms: higher perceived risk or targeted recommendations may increase uptake for some vaccines, while economic insecurity, stigma, discrimination, or limited access to culturally competent care may reduce preventive service use.

Recent studies on vaccination by sexual orientation have focused heavily on COVID-19 vaccination and show that sexual-minority vaccination patterns are not uniform across subgroups. McNaghten et al. (2022), using the National Immunization Survey Adult COVID Module from August–October 2021, found that gay and lesbian adults had higher COVID-19 vaccination coverage than heterosexual adults, while bisexual adults had coverage closer to that of heterosexual adults. The study also showed important subgroup variation: among gay/lesbian and bisexual adults, men had higher vaccination coverage than women, and vaccination coverage was particularly low among non-Hispanic Black LGBT adults. Among non-Hispanic Black adults, gay/lesbian women and bisexual women had lower coverage than heterosexual women, suggesting that sexual-orientation differences may depend on both race/ethnicity and gender.

Park and Kim (2024) also examined COVID-19 vaccination using the U.S. Census Bureau Household Pulse Survey from 2021 to 2024. In contrast to McNaghten et al. (2022), their adjusted regression results showed that both gay/lesbian and bisexual adults had higher odds of COVID-19 vaccination than heterosexual adults. However, their main contribution was not only the average sexual-orientation difference, but also the finding that pandemic-related socioeconomic hardships were associated with lower vaccine uptake and that these associations varied across sexual orientation and gender identity groups. This suggests that economic insecurity, household hardship, and social vulnerability may shape vaccination behavior differently within sexual and gender minority populations. Xu et al. (2024) similarly focused on COVID-19 testing and vaccination among youth and young adults ages 14–24. Their results showed differences in COVID-19 vaccination by age and race/ethnicity, but the study was limited to a younger online sample and does not provide the same broad adult comparison across routine vaccines.

Other recent work examines vaccination beyond COVID-19 but remains limited in scope or sample design. Polonijo and Vogelsang (2023) used 2020 Behavioral Risk Factor Surveillance System (BRFSS) data to study influenza and shingles vaccination among U.S. adults aged 50 and older and pneumococcal vaccination among adults aged 65 and older, by sexual orientation and gender identity. They found that vaccination differences vary by subgroup and vaccine type: transgender adults have lower uptake across all three vaccines, gay men are more likely than heterosexual men to receive flu and shingles vaccination, and bisexual women are less likely than heterosexual women to receive flu vaccination. Although this study provides nationally relevant evidence on routine adult vaccines, it focuses on older adults and examines only three vaccine outcomes.

Krause et al. (2024) studied LGBTQ+ adults in New Jersey and New York and examined uptake of several adult vaccines, including COVID-19, HPV, hepatitis A, hepatitis B, meningitis B, influenza, and shingles. They found that vaccine uptake varied substantially by vaccine type and by LGBTQ+ subgroup. However, because the study included only LGBTQ+ adults, it could not directly compare gay/lesbian or bisexual adults with heterosexual adults. Its regional focus on two states also limits the extent to which the findings can be generalized to all U.S. adults.

Hsieh (2024) provides especially relevant evidence on intersectional vaccination differences using NHIS data from 2013–2018, but the analysis focuses only on influenza vaccination. The study found that flu vaccination varied jointly by sexuality, gender, and race/ethnicity. White gay men had the highest predicted flu vaccination rate, while Black bisexual women had the lowest. More broadly, sexual-minority women had lower flu vaccination rates than heterosexual women across several racial and ethnic groups, whereas sexual-minority men often had similar or higher rates than heterosexual men. These findings suggest that sexual orientation should not be treated as a single uniform category; rather, vaccination differences may differ between gay/lesbian and bisexual adults and may also be shaped by gender and race/ethnicity. Together, these studies

suggest that sexual orientation is relevant for vaccination uptake, but the association may differ by vaccine type, subgroup, gender, race/ethnicity, healthcare access, and socioeconomic context.

This capstone is most closely aligned with the work of Srivastav, O'Halloran, Lu, Williams, and Hutchins (2019), who used NHIS 2013–2015 data to examine differences in adult vaccination by self-identified sexual orientation. Their analysis examined several adult vaccines, including HPV, hepatitis A, hepatitis B, influenza, pneumococcal, tetanus, and shingles vaccination. They found that vaccination patterns differed by sexual orientation and vaccine type. For example, bisexual women had higher HPV vaccination coverage than heterosexual women. Gay men and bisexual women had higher hepatitis A and hepatitis B vaccination coverage than their heterosexual counterparts. In contrast, bisexual adults had lower influenza vaccination coverage than gay/lesbian and heterosexual adults. For several other vaccines, including pneumococcal, tetanus, and shingles vaccination, differences by sexual orientation were less consistent or not statistically significant after adjustment. In their multivariable logistic regression, health status and other behavioral traits did not show a consistent association with vaccination across all groups. However, characteristics generally associated with vaccination remained independently associated with the probability of being vaccinated even after controlling for sexual orientation.

2.4. Literature Gap and Contribution of This Study

Although adult vaccination research has examined differences by race, ethnicity, gender, insurance, and healthcare access, sexual orientation remains less developed as a dimension of vaccination research, especially in health economics. One reason is that sexual orientation has not been consistently measured in health surveillance data. Using both Web and PubMed searches, Patterson et al. (2017) identified 43 data sources that included sexual orientation or transgender-inclusive gender identity measures: 7 international sources and 36 U.S.-specific sources, including 21 national and 15 state or regional sources. However, few datasets followed best-practice measurement guidelines. Only 14% measured all three dimensions of sexual orientation—identity, behavior, and attraction—and none used the recommended two-step gender identity measure based on sex assigned at birth and current gender identity (Patterson et al., 2017). In addition, because sexual minority adults represent a relatively small share of the population, researchers often face small subgroup sample sizes. As a result, some studies combine sexual minority adults into one broad category to improve statistical power, but this approach can obscure important differences between gay/lesbian and bisexual adults.

The existing post-COVID literature on vaccination by sexual orientation remains limited because much of the recent evidence focuses on COVID-19 vaccination rather than a broader set of routine adult vaccines. As a result, less is known about whether sexual-orientation differences persist across vaccines such as HPV, hepatitis A, hepatitis B, influenza, tetanus, shingles, and pneumococcal vaccination. Srivastav et al. (2019) is the study most closely related to this capstone because it also uses NHIS data and examines multiple adult vaccines by self-reported

sexual orientation. However, the present analysis differs from Srivastav et al. in both period and design: it uses more recent pooled IPUMS NHIS data from 2021–2024 and focuses on overall sexual orientation differences rather than replicating their gender-stratified and high-risk subgroup structure. In reviewing the literature, I did not identify any recent nationally representative study that compares heterosexual, gay/lesbian, and bisexual adults across multiple routine adult vaccines in the post-COVID period.

This capstone addresses that gap in three ways. First, it uses recent pooled IPUMS NHIS 2021–2024 data to examine adult vaccination uptake in the post-COVID period. Second, it examines vaccination uptake separately for heterosexual, gay/lesbian, and bisexual adults rather than combining sexual minority adults into one broad category. Third, it compares sexual-orientation differences across multiple adult vaccines and estimates both unadjusted and adjusted survey-weighted models. By controlling for demographic, socioeconomic, healthcare access, and health-related characteristics, the analysis examines whether sexual orientation differences persist after accounting for key observed covariates. In doing so, the study contributes recent evidence to the literature on adult vaccination, LGBTQ+ health, and preventive health behavior from a health economics perspective.

3. Data and Methodology

3.1. Survey Description

This study uses pooled 2021–2024 data from IPUMS NHIS, a harmonized version of the National Health Interview Survey. The NHIS is an annual, nationally representative household survey of the civilian, noninstitutionalized U.S. population. It collects information on health status, health behaviors, healthcare access, insurance coverage, demographic characteristics, and socioeconomic conditions. IPUMS Health Surveys harmonizes NHIS variables across years and allows researchers to create customized data extracts for analysis. This study uses the Sample Adult files because adult vaccination outcomes and self-reported sexual orientation are measured for sampled adults. Pooling 4 years of combined data increases the analytic sample size for sexual minority adults and supports comparisons of vaccination uptake among heterosexual, gay/lesbian, and bisexual adults. The sample size for this study was 107,498 adults aged ≥ 19 years.

3.2. Vaccine Variables

The primary outcome variables are binary indicators of adult vaccination uptake, coded as 1 if the respondent reported receiving the vaccine and 0 if the respondent reported not receiving it. Respondents with missing, refused, don't know, or not ascertained responses are excluded from the vaccine-specific analytic sample. This analysis includes eight vaccination outcomes: influenza, COVID-19, tetanus/Td, HPV, hepatitis A, hepatitis B, shingles, and pneumococcal vaccination. This study follows the CDC adult immunization schedule for adults aged 19 years

and older to define broad routine adult vaccination outcomes. Detailed vaccine-specific clinical indications and narrowly defined risk-based recommendations are not applied because eligibility for some vaccines depends on individualized clinical assessment and provider–patient interaction, which are not fully captured in the IPUMS NHIS survey data.

The analytic sample varies across vaccine outcomes because CDC adult vaccination recommendations differ by vaccine type and age group; restricting each outcome to the relevant age range helps align the analysis with the population for whom the vaccine is routinely recommended. HPV vaccination is examined among young adults aged 19–26¹, while hepatitis B vaccination is examined among adults aged 19–59². Influenza, COVID-19, and tetanus/Td vaccination are examined among adults aged 19 and older. Tetanus/Td vaccination reflects the routine adult booster recommendation, with Td/Tdap recommended every 10 years for adults. Shingles and pneumococcal vaccination are examined among adults aged 50 and older^{3,4}. Hepatitis A is included as an adult vaccination outcome available in NHIS, but the analysis does not apply detailed risk-based eligibility criteria.

In the analysis, HPV, hepatitis A, hepatitis B, shingles, and pneumonia vaccination indicate whether the respondent has ever received the respective vaccine. Influenza vaccination captures whether the respondent received a flu vaccine within the past 12 months. Tetanus/Td vaccination indicates whether the respondent received a tetanus/Td shot in the past 10 years, excluding tetanus vaccination received during pregnancy. COVID-19 vaccination is defined as whether the respondent has ever received a COVID-19 vaccine. Because vaccination questions were not collected in every NHIS survey year, HPV and tetanus/Td vaccination are analyzed using 2022 data only, hepatitis A vaccination is analyzed using 2021 and 2024 data, and hepatitis B vaccination is analyzed using 2021 and 2023 data. Therefore, sample sizes vary across vaccine outcomes.

3.3. Sexual Orientation Variable

This is the primary independent variable of interest. The sexual orientation in the dataset is used to capture the self-identified sexual orientation of sample adults aged 19 and older by asking, "Which of the following best represents how you think of yourself?" Respondents were given

¹ The Advisory Committee on Immunization Practices (ACIP) recommends routine HPV vaccination at ages 11 or 12, with vaccination allowed to begin at age 9, and catch-up vaccination through age 26 for those not adequately vaccinated. Because HPV vaccination is not routinely recommended for all adults older than age 26, and vaccination for adults ages 27–45 is based on shared clinical decision-making. This analysis restricts the HPV sample to young adults ages 19–26.

² ACIP recommends universal HepB vaccination for adults aged 19–59 years, and adults aged ≥60 years with risk factors for hepatitis B.

³ ACIP recommends recombinant 2 doses of Shingles vaccine (Now RZV; Shingrix) for adults aged 50 years and older, and for adults aged 19 years and older who are or will be immunodeficient or immunosuppressed.

⁴ Prior to October 2024, pneumococcal vaccine (PCV) was recommended for adults aged 19–64 with specific risk conditions and all those aged ≥65. On October 23, 2024, the ACIP expanded this to include a single PCV dose for all adults aged ≥50 who are PCV-naïve or have an unknown vaccination history. Risk-based recommendations for adults aged 19–49 remain unchanged.

options including "gay" or "lesbian," "straight, that is, not lesbian or gay," "bisexual," "something else," and "I don't know the answer." The wording of the question was slightly tailored based on gender, with men asked about being "gay" or "straight, that is, not gay," and women asked about being "lesbian or gay" or "straight, that is, not lesbian or gay." It is important to note a data limitation: while follow-up questions were asked to those who chose "something else" or "I don't know the answer," these detailed responses are not included in the publicly available data due to sample size constraints. Respondents who selected "something else" or "I don't know the answer" were classified as missing data and thus excluded from this analysis.

3.4. Demographics, Socio-Economic and Health-related Variables

Consistent with prior health economics and epidemiological literature, this study incorporates a comprehensive set of covariates capturing demographic characteristics, socio-economic status, health conditions, health behaviors, and healthcare access.

Demographic variables include age group (19-26, 27-49, 50-64, and ≥ 65 years), gender (male, female), and race/ethnicity (non-Hispanic White, non-Hispanic Black, Hispanic, and non-Hispanic other/multiple races).

Socio-economic characteristics comprise educational attainment (less than high school, high school/GED, and college or higher), employment status (employed vs. not employed), and poverty level. *Employment status* classifies whether sample adults were active in the workforce last week (including seasonal, contract, or paid work) or were away from work temporarily. The "No" category encompasses individuals outside the labor force as well as those who are unemployed but actively seeking work. *Poverty level* is defined using the ratio of family income to the federal poverty threshold for the given year. Individuals are classified as below poverty if the ratio is less than 1, at or near poverty if the ratio is between 1 and 2, and above poverty if the ratio is greater than 2.

Healthcare access variables include health insurance coverage (insured vs. uninsured) and having a usual place for healthcare (yes/no). Health status and clinical conditions are measured using self-reported overall health (excellent vs. other), body mass index (BMI) (normal/underweight, overweight, obese), and the presence of chronic conditions, including asthma, diabetes, heart disease, and disability status. *Disability status* is defined by the Washington Group Short Set Composite Disability Indicator, which signifies the presence of a disability related to challenges in vision, hearing, ambulation, communication, self-care (washing or dressing), or cognition (remembering or concentrating).

Finally, *travel* history is incorporated as a proxy for exposure-related risk, which is particularly relevant for vaccines such as hepatitis A and hepatitis B. Individuals reporting travel to high-risk regions are more likely to be recommended for specific vaccinations. This variable indicates

whether the respondent has traveled to any country other than Canada, Japan, Australia, New Zealand, or Europe since 1995.

3.5. Econometric Framework

This study estimates two survey-weighted logistic regression models for each vaccine outcome. *The first model* examines the unadjusted association between self-reported sexual orientation and vaccination uptake. *The second model* adds demographic, socioeconomic, healthcare-access, and health-related covariates to examine whether sexual-orientation differences persist after accounting for observed characteristics. Results are reported as average marginal effects (AMEs), which are easier to interpret than log-odds because they represent changes in vaccination probability.

Model 1: $Pr(Y_{iv} = 1 | SO_i) = \Lambda(\alpha_v + \beta_v SO_i)$

where, Y_{iv} is a binary indicator equal to 1 if individual i received vaccine v and 0 otherwise; SO_i represents self-reported sexual orientation categories, with heterosexual respondents as the reference group; α_v is the vaccine-specific intercept; β_v captures the association between sexual orientation and vaccination uptake for vaccine v ; and $\Lambda(\cdot)$ is the logistic cumulative distribution function.

The unadjusted average marginal effect (AME) for the sexual-orientation category (k) is:

$$AME_{k,v} = (1/N_v) \sum_{i=1}^{N_v} [Pr(Y_{iv} = 1 | SO_i = k) - Pr(Y_{iv} = 1 | SO_i = \text{heterosexual})]$$

AMEs represent discrete changes in predicted vaccination probabilities relative to the heterosexual reference group.

Model 2: $Pr(Y_{iv}=1 | SO_i, Z_i) = \Lambda(\alpha_v + \beta_v SO_i + \delta_v Z_i)$

Model 2 extends Model 1 by adding Z_i , which is a vector of control variables included in the vaccine-specific model. δ_v is the vector of coefficients for these controls. These controls include demographic, socioeconomic, healthcare-access, and health-related characteristics. All other terms are defined as above for Model 1.

The adjusted average marginal effect (AME) for category k is:

$$AME_{k,v} = (1/N_v) \sum_{i=1}^{N_v} [Pr(Y_{iv} = 1 | SO_i = k, Z_i) - Pr(Y_{iv} = 1 | SO_i = \text{heterosexual}, Z_i)]$$

The adjusted AME reports whether the probability of receiving vaccine differs between gay/lesbian or bisexual adults and heterosexual adults, even after holding observed covariates constant. For categorical variables, including sexual orientation, AMEs are interpreted as discrete changes in predicted probability relative to the reference group.

In addition to the pooled adjusted model, this study also estimates gender-stratified versions of Model 2 separately for male and female respondents. These models use the same survey-weighted logistic

regression framework and the same set of covariates, but the sample is restricted by gender. The gender-stratified models are estimated as:

$$Pr(Y_{iv} = 1 \mid SO_i, Z_i, G_i = g) = A(\alpha_{v,g} + \beta_{v,g}SO_i + \delta_{v,g}Z_i)$$

where $G_i = g$ indicates that the model is estimated separately for gender group g , with g representing male or female respondents. The coefficients $\beta_{v,g}$ capture the association between sexual orientation and vaccination uptake within each gender-specific sample.

The adjusted AME for sexual-orientation category k within gender group g is:

$$AME_{k,v,g} = (1 / N_{v,g}) \sum_{i=1}^{N_{v,g}} [Pr(Y_{iv} = 1 \mid SO_i = k, Z_i, G_i = g) - Pr(Y_{iv} = 1 \mid SO_i = \text{heterosexual}, Z_i, G_i = g)]$$

These gender-stratified AMEs compare gay/lesbian and bisexual respondents with heterosexual respondents within the same gender group. For example, the male-only model compares gay/lesbian males and bisexual males with heterosexual males, while the female-only model compares gay/lesbian females and bisexual females with heterosexual females. This additional analysis examines whether adjusted sexual-orientation differences in vaccination uptake vary by gender.

4. Results

4.1. Descriptive Statistics

[Table 1](#) and [Table 2](#) represent the descriptive statistics of the survey participants. [Table 1](#) presents the percentage distribution (weighted) of selected demographic, socioeconomic, healthcare-access, health-status, and health-condition characteristics among adults aged 19 years and older by self-reported sexual orientation. For categorical variables, the table reports weighted percentage distributions and unweighted sample counts.

In the pooled IPUMS NHIS 2021–2024 sample among 107,498 individuals, 95.29% of adults identified as heterosexual, 2.07% as gay/lesbian, and 2.64% as bisexual, indicating that the bisexual population share was slightly larger than the gay/lesbian share. Bisexual adults were more concentrated in younger age groups, particularly ages 19–26, than heterosexual and gay/lesbian adults, while heterosexual adults had a larger share of respondents aged 65 and older.

Gender composition also differed across groups: gay/lesbian adults were more likely to be male, whereas bisexual adults were more likely to be female. For race and ethnicity, non-Hispanic White adults made up the largest share in all three sexual-orientation groups, followed by Hispanic adults and then non-Hispanic Black adults.

Gay/lesbian adults had higher educational attainment and a higher employment rate than heterosexual adults⁵. In contrast, bisexual adults had higher poverty and lower access to healthcare, including lower rates of having a usual place for care and health insurance.

Health characteristics also differed by sexual orientation. Gay/lesbian and bisexual adults reported higher asthma prevalence than heterosexual adults, and bisexual adults reported higher disability. In contrast, heterosexual adults had higher rates of heart disease and diabetes, likely reflecting their older age distribution.

Table 1. Descriptive Statistics of the survey participants aged 19 years and older, categorized by demographic characteristics, socio-economic factors, health conditions, health status, healthcare access, and self-identified sexual orientation, derived from IPUMS NHIS 2021-2024. (Sample values are unweighted counts. Weighted % values are survey-weighted column percentages.)

	Heterosexual		Gay/Lesbian		Bisexual	
	Sample	Weighted %	Sample	Weighted %	Sample	Weighted %
Overall	107,498	95.29	2,436	2.07	2,483	2.64
Age group						
19-26	7,717	12.21	289	20.50	796	44.34
27-49	35,981	38.50	1,053	45.26	1,281	46.87
50-64	27,033	25.42	632	22.59	230	6.22
65 and older	35,793	23.86	433	11.65	128	2.58
Gender						
Male	49,378	49.32	1,427	57.90	634	24.96
Female	58,119	50.68	1,006	42.10	1,846	75.04
Race/Ethnicity						
Non-Hispanic White	71,918	62.30	1,677	66.42	1,693	68.73
Non-Hispanic Black	11,246	11.54	219	10.76	208	9.04
Hispanic	15,338	17.42	353	14.97	350	13.78
Non-Hispanic Other	8,996	8.73	187	7.85	232	8.44

⁵ This analysis stratified employment by age to see if age composition influenced sexual orientation-based differences. Findings suggest the higher non-employment rate among heterosexual respondents is partly due to a larger retirement-age population among heterosexual respondents; they had the lowest employment rate among those 65 and older. However, patterns varied: gay and lesbian respondents outpaced heterosexuals in every age group. At the same time, bisexual adults had lower employment rates than heterosexual adults among key working-age groups, particularly ages 27–49 and 50–64. Thus, while age composition partly explains heterosexual employment trends, it does not account for the disadvantage seen in working-age bisexual respondents.

	Heterosexual		Gay/Lesbian		Bisexual	
	Sample	Weighted %	Sample	Weighted %	Sample	Weighted %
Education level						
Less than HS	9,181	10.35	61	3.68	121	6.34
HS and GED	42,992	42.88	776	37.68	1,085	51.67
College and above	54,870	46.77	1,591	58.64	1,265	41.99
Employment status^a						
Employed	61,263	62.85	1,730	74.03	1,804	72.00
Not employed	45,954	37.15	705	25.97	675	28.00
Poverty level^b						
Above poverty	77,832	72.86	1,917	78.32	1,619	64.92
At or near poverty	18,966	17.54	323	13.22	500	20.68
Below poverty	10,700	9.61	196	8.45	364	14.39
Self-selected health status						
Excellent/very good	58,988	56.65	1,437	60.66	1,294	52.29
Other	48,471	43.35	998	39.34	1,189	47.71
BMI status						
Normal and below weight	34,400	32.42	859	36.96	921	38.40
Overweight	36,326	34.24	781	30.78	631	24.46
Obese	34,651	33.34	770	32.25	894	37.14
Usual place for healthcare						
Yes	98,102	89.95	2,225	90.83	2,140	85.13
No	9,330	10.05	210	9.17	342	14.87
Health insurance						
Yes	99,521	90.81	2,293	93.52	2,234	88.76
No	7,720	9.19	140	6.48	241	11.24
Asthma						
Yes	14,971	14.03	462	20.00	650	27.25
No	92,440	85.97	1,974	80.00	1,831	72.75
Heart disease						
Yes	6,938	5.12	97	3.05	47	1.14
No	100,260	94.88	2,335	96.95	2,432	98.86
Diabetes						
Yes	12,086	10.03	186	6.29	109	4.05
No	95,331	89.97	2,248	93.71	2,373	95.95

	Heterosexual		Gay/Lesbian		Bisexual	
	Sample	Weighted %	Sample	Weighted %	Sample	Weighted %
Disability						
Yes	11,370	9.03	220	8.88	311	12.91
No	96,126	90.97	2,216	91.12	2,172	87.09
Travel						
Yes	33,055	40.77	901	46.74	794	36.69
No	49,596	59.23	961	53.26	1,119	63.31

Note:

- ^a Employment status classifies whether sample adults were active in the workforce last week (including seasonal, contract, or paid work) or were away from work temporarily. The "No" category encompasses individuals outside the labor force as well as those who are unemployed but actively seeking work.
- ^b Poverty level is defined using the ratio of family income to the federal poverty threshold for the given year. Individuals are classified as below poverty if the ratio is less than 1, at or near poverty if the ratio is between 1 and 2, and above poverty if the ratio is greater than 2.
- This analysis also stratified employment by age to see if age composition influenced sexual orientation-based differences. Findings suggest the higher non-employment rate among heterosexual respondents is partly due to a larger retirement-age population among heterosexual respondents; they had the lowest employment rate among those 65 and older. However, patterns varied: gay and lesbian respondents outpaced heterosexuals in every age group. At the same time, bisexual adults had lower employment rates than heterosexual adults among key working-age groups, particularly ages 27–49 and 50–64. Thus, while age composition partly explains heterosexual employment trends, it does not account for the disadvantage seen in working-age bisexual respondents.

[Table 2](#) presents survey-weighted, unadjusted vaccination coverage(%) among U.S. adults by self-identified sexual orientation. The results show substantial variation in vaccination uptake across sexual-orientation groups, and the direction of the differences varies by vaccine type.

Overall, among 1973 individuals aged 19–26 years, 46.42% were vaccinated against HPV. Bisexual adults had the highest HPV uptake at 69.50%, compared with 53.61% among gay/lesbian adults and 43.20% among heterosexual adults. The bisexual estimate was significantly higher than the heterosexual estimate and also significantly different from the gay/lesbian estimate. The gay/lesbian HPV estimate should be interpreted cautiously because the gay/lesbian subgroup has a small sample size and a wide confidence interval.

For hepatitis A and hepatitis B vaccination, both sexual minority groups had higher unadjusted vaccination coverage than heterosexual adults. Hepatitis A vaccination coverage rate was significantly higher among gay/lesbian adults and bisexual adults than among heterosexual adults (42.86% and 45.05%, respectively). Hepatitis B vaccination showed a similar pattern, with significantly higher uptake among gay/lesbian adults and bisexual adults than among heterosexual adults (59.90% and 51.65%, respectively). For hepatitis B, the gay/lesbian estimate was also significantly higher than the bisexual estimate.

For influenza vaccination, the unadjusted pattern differed from hepatitis A and hepatitis B. Gay/lesbian adults had a significantly higher flu vaccination rate (54.12%) than heterosexual

Table 2. Survey-weighted unadjusted vaccination proportions (%) of selected vaccines among U.S. adults by self-identified sexual orientation, IPUMS NHIS 2021-2024. (Sample values are unweighted counts. Weighted proportions are survey-weighted percentages with 95% confidence intervals.)

Vaccines	Sexual Orientation							
	Overall		Heterosexual		Gay/Lesbian		Bisexual	
	N	Weighted proportion % (95% CI) ^c	N	Weighted proportion % (95% CI)	N	Weighted proportion % (95% CI)	N	Weighted proportion % (95% CI)
HPV^d 19-26	1,973	46.42 (43.79, 49.05)	1,564	43.20 (40.32, 46.09)	63	53.61 (39.10, 68.12)	183	69.50^{a***,b*} (61.90, 77.09)
Hepatitis A 19+	54,012	26.64 (25.99, 27.30)	49,686	25.82 (25.16, 26.48)	1,141	42.86^{a***} (39.13, 46.59)	1,133	45.05^{a***} (41.45, 48.65)
Hepatitis B 19-59	26,322	40.04 (39.18, 40.90)	23,906	39.24 (38.36, 40.13)	665	59.90^{a***} (55.28, 64.51)	658	51.65^{a***, b***} (47.28, 56.03)
Flu 19+	116,002	46.86 (46.25, 47.46)	106,113	47.03 (46.41, 47.64)	2,397	54.12^{a***} (51.38, 56.86)	2,420	41.37^{a***, b***} (38.94, 43.80)
Tetanus (Td) 19+	25,265	58.82 (57.78, 59.85)	22,952	58.83 (57.75, 59.91)	530	66.36^{a***} (61.59, 71.12)	514	61.77 (56.78, 66.76)
COVID-19 19+	108,607	77.61 (77.01, 78.22)	99,357	77.36 (76.74, 77.97)	2,227	88.32^{a***} (86.48, 90.15)	2,299	80.50^{a***, b***} (78.32, 82.68)
Shingles 50+	65,894	38.21 (37.52, 38.90)	62,140	38.13 (37.43, 38.83)	1,057	52.53^{a***} (48.99, 56.07)	352	38.67^{b***} (32.81, 44.52)
Pneumonia 50+	65,266	41.58 (41.02, 42.14)	61,536	41.59 (41.02, 42.16)	1,038	45.59^{a**} (42.08, 49.09)	343	36.66^{b**} (30.23, 43.10)

Note:

- ^a *** $p < 0.01$, ** $p < 0.05$, * $p < 0.1$, comparing against heterosexual.
- ^b *** $p < 0.01$, ** $p < 0.05$, * $p < 0.1$, comparing against gay/ lesbian.
- ^c CI is the confidence interval.
- The vaccine age group is based on the CDC-recommended routine vaccination for adults and excludes special situations: [Recommended Vaccinations for Adults](#)
- ^d Data on the Human Papillomavirus (HPV) vaccine were available only for 2022. Due to a comparatively small sample size

for the subgroup, the HPV vaccination estimate for gay or lesbian adults between the ages of 19 and 26 is less precise. This results in a broader confidence interval and a larger standard error; therefore, these findings should be interpreted with caution.

Figure 1: Survey-weighted Unadjusted Vaccination Coverage by Sexual Orientation, Part 1





Figure 2: Survey-weighted Unadjusted Vaccination Coverage by Sexual Orientation, Part 2



adults; in contrast, bisexual adults had a significantly lower rate (41.37%) than both heterosexual and gay/lesbian adults. COVID-19 vaccination was higher among both gay/lesbian and bisexual adults than among heterosexual adults, but the gay/lesbian estimate remained significantly higher than the bisexual estimate (88.32% vs 80.50%).

For tetanus/Td vaccination, gay/lesbian adults had a significantly higher unadjusted vaccination proportion than heterosexual adults, while bisexual adults did not differ significantly from heterosexual adults.

For shingles and pneumococcal vaccination, gay/lesbian adults again had a higher uptake than heterosexual adults. However, the vaccination rate among bisexual adults was significantly lower than that of gay/lesbian adults for both of these vaccines. Bisexual adults also had a lower vaccination coverage for Pneumonia than the heterosexual population, although the estimate was not statistically significant. [Figure 1](#) and [Figure 2](#) visually summarize the survey-weighted vaccination proportions (%) from [Table 2](#), highlighting differences in vaccine uptake across sexual orientation groups.

4.2. Results From Logistic Regression

[Tables 3](#) and [4](#) extend the descriptive evidence from [Tables 1](#) and [2](#) by estimating average marginal effects from survey-weighted logistic regression models. While [Table 1](#) describes how respondent characteristics differ by sexual orientation, and [Table 2](#) reports unadjusted vaccination proportions, [Tables 3](#) and [4](#) quantify the association between sexual orientation and vaccination uptake in a logistic regression framework. This allows the study to express the difference between gay/lesbian or bisexual adults and heterosexual adults as a percentage-point difference in the probability of vaccination uptake, with statistical significance and confidence intervals.

[Table 3](#) presents [Model 1](#); the baseline specification without controlling for individual covariates. In this bivariate model, sexual orientation is the only explanatory variable. In the unadjusted model, gay or lesbian adults have significantly higher vaccination uptake than heterosexual adults for most vaccine outcomes. For the hepatitis A vaccine, the average marginal effect is 0.170, which indicates that the probability of receiving a hepatitis A vaccination is, on average, 17.0 percentage points higher for individuals in the gay/lesbian group compared to those in the heterosexual group, and significant at the 1% level. Similarly, for the hepatitis B vaccination, there is a 20.7 percentage point higher probability for gay/lesbian individuals to vaccinate relative to heterosexual adults, significant at the 1% level.

Gay or lesbian adults also have significantly higher uptake for flu, tetanus, COVID-19, shingles, and pneumonia vaccination. The HPV estimate is positive but not statistically significant, indicating that the baseline model does not provide sufficient evidence of a difference in HPV vaccination for gay or lesbian adults.

For bisexual adults, the unadjusted model shows significant positive differences for HPV, hepatitis A, hepatitis B, and COVID-19 vaccination. The AME for HPV is 0.263, meaning a 26.3 percentage point higher probability of receiving HPV vaccination for bisexuals relative to heterosexual adults, significant at the 1% level. The AMEs for hepatitis A and hepatitis B are 0.192 and 0.124, respectively, also significant at the 1% level. In contrast, the flu AME is -0.057, meaning a 5.7 percentage point decrease in flu vaccination relative to heterosexual adults, significant at the 1% level. The estimates for tetanus, shingles, and pneumonia vaccination are not statistically significant.

Table 3: Average Marginal Effects of Sexual Orientation on Vaccination Uptake, Unadjusted (Model 1), data from IPUMS NHIS 2021-2024.

Sexual Orientation	HPV (19-26)	Hepatitis A (19+)	Hepatitis B (19-59)	Flu (19+)	Tetanus (Td) (19+)	COVID-19 (19+)	Shingles (50+)	Pneumonia (50+)
	AME SE (95% CI)	AME SE (95% CI)	AME SE (95% CI)	AME SE (95% CI)	AME SE (95% CI)	AME SE (95% CI)	AME SE (95% CI)	AME SE (95% CI)
Heterosexual	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group
Gay or Lesbian	0.104 (0.075) [-0.044, 0.252]	0.170*** (0.019) [0.133, 0.208]	0.207*** (0.024) [0.160, 0.253]	0.071*** (0.014) [0.044, 0.098]	0.075*** (0.025) [0.027, 0.124]	0.110*** (0.009) [0.091, 0.128]	0.144*** (0.018) [0.108, 0.180]	0.040** (0.018) [0.004, 0.075]
Bisexual	0.263*** (0.041) [0.182, 0.344]	0.192*** (0.018) [0.156, 0.228]	0.124*** (0.022) [0.080, 0.168]	-0.057*** (0.012) [-0.080, -0.033]	0.029 (0.026) [-0.021, 0.080]	0.031*** (0.011) [0.010, 0.053]	0.005 (0.030) [-0.053, 0.064]	-0.049 (0.033) [-0.113, 0.015]
Analytic Subpopulation N	1810	51,960	25, 229	110, 930	23, 996	103, 883	63, 549	62, 917

Notes:

1. AMEs are average marginal effects from survey-weighted logistic models. Heterosexuals are the reference group.
2. Standard errors are shown in parentheses, and 95% confidence intervals are shown in brackets.
3. * p < 0.10, ** p < 0.05, *** p < 0.01.
4. Analyses are restricted to survey years in which each vaccination variable was available; therefore, sample sizes differ across the vaccines.
5. Data on the Human Papillomavirus (HPV) vaccine were available only for 2022. Due to a comparatively small sample size for the subgroup, the HPV vaccination estimate for gay or lesbian adults between the ages of 19 and 26 is less precise. This results in a broader confidence interval and a larger standard error; therefore, these findings should be interpreted with caution.
6. Hepatitis A data were available in 2021 and 2024.
7. Hepatitis B data were available in 2021 and 2023.
8. Data on the Tetanus vaccine were available only for 2022.
9. Analyses are restricted to survey years in which each vaccination variable was available; therefore, sample sizes vary by vaccination.

[Table 4](#) presents the adjusted specification ([Model 2](#)), which conditions on observable covariates including demographic characteristics, socioeconomic status, healthcare access, health insurance, and selected health conditions. This adjusted model shows whether sexual-orientation differences remain after accounting for factors such as age, gender, race and ethnicity, education, employment, poverty status, usual place for healthcare, health insurance, smoking, alcohol use, and selected health conditions. Therefore, [Table 4](#) helps distinguish raw group differences from differences that persist after conditioning on observable characteristics.

After adjustment, gay or lesbian adults remain significantly more likely than heterosexual adults to have several adult vaccines. The hepatitis B AME is 0.164, meaning on average a 16.4 percentage point higher probability of receiving the hepatitis B vaccine relative to comparable heterosexual adults, significant at the 1% level. The shingles AME is 0.129, meaning a 12.9 percentage point increase, and the COVID-19 AME is 0.111, meaning an 11.1 percentage point increase. Gay or lesbian adults also have significantly higher adjusted uptake for hepatitis A, flu, and pneumonia vaccination. The HPV and tetanus estimates are positive but not statistically significant after covariate adjustment.

Table 4: Adjusted Average Marginal Effects on Vaccination Uptake (Model 2)

	HPV (19-26)	Hepatitis A (19+)	Hepatitis B (19-59)	Flu (19+)	Tetanus/ Td (19+)	COVID-19 (19+)	Shingles (50+)	Pneumonia (50+)
	AME SE (95% CI)	AME SE (95% CI)	AME SE (95% CI)	AME SE (95% CI)	AME SE (95% CI)	AME SE (95% CI)	AME SE (95% CI)	AME SE (95% CI)
Sexual Orientation								
Heterosexual	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group
Gay or Lesbian	0.039 (0.069) [-0.095, 0.174]	0.104*** (0.017) [0.070, 0.139]	0.164*** (0.023) [0.119, 0.209]	0.092*** (0.012) [0.067, 0.116]	0.038 (0.025) [-0.011, 0.088]	0.111*** (0.009) [0.094, 0.128]	0.129*** (0.017) [0.096, 0.162]	0.084*** (0.015) [0.053, 0.114]
Bisexual	0.186*** (0.041) [0.107, 0.266]	0.078*** (0.016) [0.046, 0.110]	0.043* (0.023) [-0.003, 0.089]	0.036*** (0.011) [0.014, 0.058]	0.028 (0.026) [-0.023, 0.079]	0.092*** (0.008) [0.076, 0.109]	0.044 (0.028) [-0.012, 0.099]	0.000 (0.026) [-0.051, 0.052]
Age group								
19-26	—	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	—	—
27-49	—	-0.132*** (0.011) [-0.154, -0.110]	-0.122*** (0.014) [-0.151, -0.094]	0.013* (0.007) [-0.001, 0.026]	-0.003 (0.014) [-0.031, 0.025]	0.005 (0.007) [-0.008, 0.018]	—	—
50-64	—	-0.241*** (0.011) [-0.263, -0.218]	-0.243*** (0.015) [-0.272, -0.214]	0.105*** (0.007) [0.090, 0.120]	-0.003 (0.016) [-0.033, 0.028]	0.107*** (0.007) [0.093, 0.120]	Reference Group	Reference Group
65 and above	—	-0.289*** (0.012) [-0.313, -0.266]	—	0.276*** (0.008) [0.260, 0.291]	-0.058*** (0.016) [-0.090, -0.027]	0.185*** (0.007) [0.171, 0.199]	0.175*** (0.005) [0.165, 0.185]	0.337*** (0.006) [0.326, 0.348]
Gender								
Male	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group
Female	0.179*** (0.026) [0.128, 0.229]	0.017*** (0.005) [0.007, 0.027]	0.067*** (0.008) [0.052, 0.082]	0.056*** (0.004) [0.048, 0.063]	-0.017** (0.008) [-0.032, -0.001]	0.012*** (0.003) [0.006, 0.019]	0.016*** (0.004) [0.008, 0.023]	0.035*** (0.004) [0.028, 0.042]

	HPV (19-26)	Hepatitis A (19+)	Hepatitis B (19-59)	Flu (19+)	Tetanus/ Td (19+)	COVID-19 (19+)	Shingles (50+)	Pneumonia (50+)
	AME SE (95% CI)	AME SE (95% CI)	AME SE (95% CI)	AME SE (95% CI)	AME SE (95% CI)	AME SE (95% CI)	AME SE (95% CI)	AME SE (95% CI)
Race/Ethnicity								
Non-Hispanic White	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group
Non-Hispanic Black	-0.054 (0.042) [-0.135, 0.028]	-0.020** (0.008) [-0.036, -0.004]	-0.068*** (0.013) [-0.093, -0.044]	-0.057*** (0.006) [-0.069, -0.044]	-0.172*** (0.013) [-0.198, -0.146]	0.030*** (0.006) [0.018, 0.043]	-0.082*** (0.007) [-0.096, -0.068]	-0.047*** (0.006) [-0.059, -0.035]
Hispanic	-0.004 (0.030) [-0.062, 0.055]	-0.000 (0.008) [-0.015, 0.015]	-0.041*** (0.011) [-0.062, -0.020]	0.000 (0.007) [-0.013, 0.013]	-0.074*** (0.013) [-0.099, -0.049]	0.108*** (0.005) [0.099, 0.117]	-0.036*** (0.008) [-0.052, -0.019]	-0.074*** (0.007) [-0.087, -0.061]
Non-Hispanic Other	0.019 (0.039) [-0.057, 0.095]	0.038*** (0.010) [0.019, 0.057]	0.032** (0.013) [0.007, 0.057]	0.056*** (0.007) [0.042, 0.070]	-0.079*** (0.014) [-0.106, -0.052]	0.120*** (0.006) [0.109, 0.132]	0.010 (0.010) [-0.009, 0.029]	-0.048*** (0.008) [-0.063, -0.033]
Education level								
Less than HS	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group
HS and GED	0.174*** (0.054) [0.069, 0.280]	0.034*** (0.009) [0.015, 0.052]	0.078*** (0.017) [0.045, 0.111]	-0.001 (0.007) [-0.015, 0.013]	0.063*** (0.015) [0.032, 0.093]	0.043*** (0.007) [0.030, 0.057]	0.040*** (0.007) [0.027, 0.053]	0.032*** (0.006) [0.021, 0.043]
College and above	0.297*** (0.057) [0.185, 0.409]	0.116*** (0.010) [0.096, 0.135]	0.177*** (0.017) [0.144, 0.210]	0.122*** (0.008) [0.107, 0.137]	0.145*** (0.016) [0.113, 0.177]	0.172*** (0.007) [0.157, 0.186]	0.128*** (0.007) [0.114, 0.142]	0.055*** (0.006) [0.043, 0.067]
Employment status								
Employed	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group
Not employed	0.047 (0.033) [-0.018, 0.112]	0.012* (0.006) [-0.001, 0.024]	0.002 (0.010) [-0.017, 0.022]	0.031*** (0.005) [0.022, 0.040]	-0.007 (0.010) [-0.026, 0.013]	-0.007 (0.004) [-0.015, 0.001]	0.070*** (0.005) [0.060, 0.080]	0.095*** (0.005) [0.086, 0.104]
Poverty level								
Above poverty	0.056 (0.038) [-0.019, 0.132]	-0.004 (0.010) [-0.023, 0.015]	0.010 (0.015) [-0.020, 0.039]	0.071*** (0.007) [0.056, 0.086]	0.055*** (0.015) [0.026, 0.084]	0.104*** (0.007) [0.091, 0.118]	0.100*** (0.007) [0.085, 0.114]	0.041*** (0.006) [0.028, 0.053]
At or near poverty	-0.010 (0.043) [-0.095, 0.075]	-0.016 (0.010) [-0.036, 0.004]	0.008 (0.016) [-0.024, 0.040]	0.007 (0.008) [-0.008, 0.022]	0.023 (0.015) [-0.007, 0.053]	0.025*** (0.007) [0.011, 0.039]	0.002 (0.008) [-0.013, 0.018]	0.016** (0.007) [0.002, 0.030]
Below poverty	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group
BMI status								
Normal and below weight	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group
Overweight	-0.028 (0.032) [-0.091, 0.035]	-0.013** (0.006) [-0.023, -0.002]	0.003 (0.009) [-0.015, 0.020]	0.008** (0.004) [0.000, 0.017]	0.008 (0.009) [-0.010, 0.026]	-0.001 (0.004) [-0.008, 0.007]	0.003 (0.005) [-0.006, 0.013]	0.004 (0.004) [-0.004, 0.012]
Obese	-0.067** (0.032) [-0.129, -0.004]	-0.006 (0.006) [-0.018, 0.005]	-0.000 (0.009) [-0.018, 0.017]	0.005 (0.005) [-0.004, 0.014]	0.013 (0.009) [-0.005, 0.031]	-0.005 (0.004) [-0.013, 0.003]	-0.002 (0.005) [-0.011, 0.008]	0.023*** (0.004) [0.015, 0.031]
Usual place for healthcare								
Yes	0.081** (0.033) [0.017, 0.145]	0.030*** (0.009) [0.012, 0.047]	0.046*** (0.012) [0.021, 0.070]	0.173*** (0.007) [0.159, 0.186]	0.120*** (0.014) [0.093, 0.148]	0.060*** (0.006) [0.048, 0.072]	0.149*** (0.009) [0.131, 0.167]	0.138*** (0.008) [0.122, 0.153]
No	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group
Health insurance								

	HPV (19-26)	Hepatitis A (19+)	Hepatitis B (19-59)	Flu (19+)	Tetanus/ Td (19+)	COVID-19 (19+)	Shingles (50+)	Pneumonia (50+)
	AME SE (95% CI)	AME SE (95% CI)	AME SE (95% CI)	AME SE (95% CI)	AME SE (95% CI)	AME SE (95% CI)	AME SE (95% CI)	AME SE (95% CI)
Yes	0.173*** (0.042) [-0.091, 0.255]	0.056*** (0.009) [-0.038, 0.074]	0.092*** (0.014) [-0.066, 0.119]	0.173*** (0.008) [-0.158, 0.188]	0.087*** (0.015) [-0.056, 0.117]	0.096*** (0.007) [-0.083, 0.109]	0.187*** (0.011) [-0.165, 0.209]	0.111*** (0.011) [-0.089, 0.133]
No	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group
Asthma								
Yes	0.009 (0.035) [-0.060, 0.079]	0.035*** (0.007) [-0.021, 0.048]	0.049*** (0.010) [-0.028, 0.070]	0.035*** (0.005) [-0.025, 0.045]	0.057*** (0.010) [-0.037, 0.077]	0.012*** (0.004) [-0.003, 0.021]	0.027*** (0.006) [-0.016, 0.039]	0.110*** (0.006) [-0.098, 0.122]
No	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group
Heart disease								
Yes	—	-0.007 (0.011) [-0.028, 0.014]	-0.022 (0.027) [-0.076, 0.032]	0.063*** (0.007) [-0.049, 0.078]	0.019 (0.016) [-0.013, 0.050]	0.010 (0.007) [-0.005, 0.024]	0.000 (0.006) [-0.013, 0.013]	0.065*** (0.006) [-0.053, 0.078]
No	—	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group
Diabetes								
Yes	0.133 (0.118) [-0.099, 0.365]	0.008 (0.009) [-0.008, 0.025]	0.037** (0.016) [-0.006, 0.068]	0.096*** (0.006) [-0.085, 0.107]	0.017 (0.012) [-0.007, 0.040]	0.047*** (0.005) [-0.037, 0.057]	0.028*** (0.006) [-0.017, 0.039]	0.108*** (0.006) [-0.096, 0.121]
No	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group
Disability								
Yes	0.065 (0.057) [-0.047, 0.176]	-0.008 (0.009) [-0.025, 0.009]	0.017 (0.016) [-0.015, 0.049]	0.008 (0.006) [-0.003, 0.020]	-0.002 (0.013) [-0.028, 0.024]	-0.015*** (0.006) [-0.026, -0.004]	-0.031*** (0.006) [-0.042, -0.020]	0.036*** (0.006) [-0.025, 0.047]
No	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group	Reference Group
Travel								
Yes	—	0.108*** (0.005) [-0.098, 0.118]	0.100*** (0.008) [-0.084, 0.115]	—	—	—	—	—
No	—	Reference Group	Reference Group	—	—	—	—	—
Analytic Sample Size (N)	1,758	50,389	24,466	107,625	23,284	100,846	61,505	60,914

Notes:

1. AMEs are average marginal effects from survey-weighted logistic regression models.
2. Standard errors are shown in parentheses and 95% confidence intervals in brackets.
3. Stars indicate statistical significance: * $p < 0.10$, ** $p < 0.05$, *** $p < 0.01$.
4. An em dash indicates that the variable was omitted from the vaccine-specific regression analysis.
5. Analyses are restricted to survey years in which each vaccination variable was available; therefore, sample sizes differ across the vaccines.
6. Sample sizes are unweighted and refer to the vaccine-specific analytic subpopulation used in the logistic regression model before estimating average marginal effects. Survey weights are used for all estimates.
7. Heart disease was excluded from the logistic regression model for HPV vaccination because no cases were observed.
8. Travel history is used as a control variable for Hepatitis A and B analysis due to its significant role in transmission

For bisexual adults, the adjusted estimates remain significant for the HPV vaccine, hepatitis A, hepatitis B, flu, and COVID-19 vaccination. The HPV AME is 0.186, meaning that bisexual adults have an 18.6 percentage point higher likelihood of being vaccinated for HPV relative to the otherwise comparable heterosexual adults, holding covariates constant. The COVID-19 AME is 0.092, meaning a 9.2 percentage point increase, and the hepatitis A AME is 0.078, meaning an 7.8 percentage point increase. The hepatitis B estimate is smaller and only marginally significant, which is different from unadjusted Model 1. The adjusted estimates for tetanus, shingles, and pneumonia vaccination are not statistically significant.

The comparison between [Tables 3](#) and [4](#) suggests that observable characteristics explain part, but not all, of the raw differences in vaccination uptake by sexual orientation. A notable change appears for flu vaccination among bisexual adults. In the unadjusted model (Model 1 and Table 3), the AME is -0.057, indicating a 5.7 percentage point decrease relative to heterosexual adults. After controlling for covariates (Model 2 and [Table 4](#)), the AME becomes 0.036, indicating a 3.6 percentage point increase in the probability of reporting the flu vaccine. This reversal suggests that the negative raw difference was influenced by compositional differences between bisexual and heterosexual adults rather than a lower adjusted association with flu vaccination.

The control variables in [Table 4](#) show expected patterns. Education, health insurance, and having a usual place for care are generally positively associated with vaccination uptake. Other covariates, including age, gender, race/ethnicity, and health conditions, vary across vaccine outcomes. These estimates should be interpreted as conditional associations because they are adjusted for the full set of covariates included in the model.

4.3. Gender-Stratified Results by Sexual Orientation

[Table 5](#) presents adjusted average marginal effects from Model 2 estimated separately for male and female respondents. These models use the same survey-weighted logistic regression framework and the same covariates as the main adjusted model (Model 2), except that gender is excluded because the models are stratified by gender. The estimates compare gay/lesbian and bisexual respondents with heterosexual respondents within the same gender group. Therefore, the male-only model compares gay/lesbian males and bisexual males with heterosexual males, while the female-only model compares gay/lesbian females and bisexual females with heterosexual females.

In the male-only model, both gay/lesbian males and bisexual males have positive and statistically significant AMEs for hepatitis A, hepatitis B, flu, and COVID-19 vaccination compared with heterosexual males. For hepatitis A, hepatitis B, flu, and COVID-19, gay/lesbian males have 15.1, 22.2, 14.7, and 13.3 percentage-point higher probabilities, and bisexual males have 11.4, 9.4, 7.9, and 12.3 percentage-point higher probabilities of reporting the respective vaccinations, compared with heterosexual males.

Table 5: Adjusted Average Marginal Effects on Vaccination Uptake (Model 2) by Male and Female Respondents

	HPV (19-26)	Hepatitis A (19+)	Hepatitis B (19-59)	Flu (19+)	Tetanus (Td) (19+)	COVID-19 (19+)	Shingles (50+)	Pneumonia (50+)
	AME SE (95% CI)	AME SE (95% CI)	AME SE (95% CI)	AME SE (95% CI)	AME SE (95% CI)	AME SE (95% CI)	AME SE (95% CI)	AME SE (95% CI)
Male Only Model (<i>Heterosexual Male is the Reference Group</i>)								
Gay or Lesbian Male	-0.022 (0.103) [-0.224, 0.179]	0.151*** (0.023) [0.107, 0.195]	0.222*** (0.029) [0.165, 0.279]	0.147*** (0.015) [0.118, 0.176]	0.040 (0.033) [-0.024, 0.104]	0.133*** (0.011) [0.111, 0.154]	0.180*** (0.022) [0.138, 0.223]	0.119*** (0.020) [0.080, 0.157]
Bisexual Male	0.275*** (0.096) [0.088, 0.463]	0.114*** (0.031) [0.053, 0.175]	0.094** (0.046) [0.002, 0.185]	0.079*** (0.022) [0.037, 0.122]	0.050 (0.052) [-0.052, 0.152]	0.123*** (0.013) [0.096, 0.149]	0.069 (0.042) [-0.014, 0.152]	-0.006 (0.029) [-0.064, 0.051]
Analytic Subpopulatio n (N)	854	23,395	11,593	49,744	10,857	46,591	27,698	27,382
Female Only Model (<i>Heterosexual Female is the Reference Group</i>)								
Gay or Lesbian Female	0.113 (0.091) [-0.067, 0.292]	0.033 (0.026) [-0.019, 0.085]	0.080** (0.035) [0.011, 0.149]	0.009 (0.019) [-0.029, 0.047]	0.045 (0.041) [-0.036, 0.126]	0.080*** (0.015) [0.051, 0.108]	0.050** (0.024) [0.003, 0.096]	0.026 (0.022) [-0.016, 0.068]
Bisexual Female	0.169*** (0.043) [0.085, 0.254]	0.059*** (0.020) [0.021, 0.098]	0.021 (0.027) [-0.033, 0.075]	0.010 (0.014) [-0.017, 0.037]	0.037 (0.029) [-0.021, 0.095]	0.079*** (0.010) [0.059, 0.098]	0.028 (0.037) [-0.044, 0.100]	-0.000 (0.037) [-0.072, 0.072]
Analytic Subpopulatio n (N)	904	26,994	12,873	57,881	12,427	54,255	33,807	33,532
Note: Models are estimated separately for male and female respondents using survey-weighted logistic regressions. Reported estimates are average marginal effects relative to heterosexual adults. Standard errors are in parentheses, and 95% confidence intervals are in brackets. All models adjust for age group, race/ethnicity, education, employment status, poverty level, health status, BMI, usual source of care, health insurance, asthma, heart disease, diabetes, and disability, where applicable. Hepatitis A and hepatitis B models additionally adjust for travel. Gender is excluded because models are stratified by gender. $p < 0.10$, $p < 0.05$, $p < 0.01$.								

For vaccine outcomes where the two male sexual-minority groups differ, gay/lesbian males also have positive and statistically significant AMEs for shingles and pneumonia vaccination, with 18.0 and 11.9 percentage points more likely to report compared with heterosexual males. In contrast, bisexual males have a positive and statistically significant AME for HPV vaccination, indicating a 27.5 percentage point higher probability compared with heterosexual males. The HPV estimate for gay/lesbian males, the tetanus estimates for both gay/lesbian and bisexual

males, and the shingles and pneumonia estimates for bisexual males are not statistically significant.

In the female-only model, both gay/lesbian females and bisexual females have positive and statistically significant AMEs for COVID-19 vaccination compared with heterosexual females. Gay/lesbian females have an 8.0 percentage point higher probability, and bisexual females have a 7.9 percentage point higher probability of reporting COVID-19 vaccination compared with heterosexual females.

In cases where results diverge between the two female sexual-minority categories, gay or lesbian females exhibit positive, statistically significant AMEs for shingles and hepatitis B vaccinations. Specifically, they demonstrate 5.0 and 8.0 percentage point increases in the likelihood of reporting vaccination, respectively, when compared to heterosexual females. For bisexual females, the largest statistically significant estimate is for HPV vaccination. The AME is 0.169, indicating a 16.9 percentage point higher probability of reporting HPV vaccination compared with heterosexual females. The AME for hepatitis A is 0.059 and statistically significant for bisexual females. All other vaccine estimates are not statistically significant within the respective female sexual-orientation subgroups.

4.4. Robustness Checks, Sensitivity Analyses, and Heterogeneity Analysis

[Appendices A1–A5](#) report additional analyses used to assess whether the main findings are robust to alternative model specifications and coding decisions. [Appendix A1](#) estimates an adjusted Linear Probability Model as an alternative to the main survey-weighted logistic regression specification. The findings demonstrate a high degree of consistency with the adjusted logistic regression estimates presented in [Table 4](#), which indicates that the primary conclusions of this study are robust to the selection of a nonlinear functional form.

[Appendix A2](#) presents a sensitivity analysis that combines gay/lesbian and bisexual respondents into a single sexual minority category. This specification tests whether the findings are sensitive to the way sexual orientation is categorized. The results show positive and statistically significant AMEs for the combined sexual minority group across all vaccine outcomes, with the tetanus (Td) vaccine outcome being marginally significant. Although this pooled specification masks differences between gay/lesbian and bisexual adults, as shown in the main analysis.

[Appendix A3](#) adds survey year fixed effects to the adjusted logistic regression models. This specification accounts for common year-specific differences in vaccination uptake across survey years. The results remain largely consistent with the main adjusted models, indicating that the main sexual-orientation patterns are not driven primarily by differences across survey years.

[Appendix A5](#) further examines whether adjusted sexual-orientation differences in vaccination uptake vary across selected demographic and socioeconomic subgroups. The analysis focuses on

hepatitis A, hepatitis B, influenza, and COVID-19 vaccination because these outcomes have sufficient sample sizes for subgroup comparisons. The table reports AMEs separately within each subgroup category. Therefore, each estimate compares gay/lesbian or bisexual adults with heterosexual adults in the same subgroup category. For example, in the urban-rural analysis, the metro gay/lesbian AME compares gay/lesbian adults living in metro areas with heterosexual adults living in metro areas. The non-metro gay/lesbian AME compares gay/lesbian adults living in non-metro areas with heterosexual adults living in non-metro areas. The same within-subgroup interpretation applies to marital status, children in the household, education, and race/ethnicity. The table also reports differences in AMEs across subgroup categories, which indicate whether the gay/lesbian-heterosexual or bisexual-heterosexual vaccination gap is significantly larger or smaller in one subgroup than another.

For marital status, the results show that gay/lesbian and bisexual adults generally have higher adjusted vaccination probabilities than heterosexual adults within both married and other marital-status groups. However, the size of the sexual-orientation gap does not differ significantly by marital status for most vaccines. The main exception is COVID-19 vaccination, where the sexual-orientation gap is smaller among married respondents than among respondents in other marital-status categories. For gay/lesbian adults, the difference in AMEs for COVID-19 is -0.064 and statistically significant. For bisexual adults, the corresponding difference is -0.032 and also statistically significant. This suggests that the higher COVID-19 vaccination probability among sexual minority adults relative to heterosexual adults is more pronounced among non-married or other marital-status respondents than among married respondents.

For children in the household, gay/lesbian adults without kids are significantly more likely than heterosexual adults without kids to report Hepatitis A, Hepatitis B, flu, and COVID-19 vaccination. Among gay/lesbian adults with kids, the estimates are smaller and mostly not statistically significant. For bisexual adults, the AMEs are generally positive, indicating higher adjusted vaccination uptake than heterosexual adults within the same kids/no-kids subgroup. But there is limited evidence that the bisexual-heterosexual gap differs systematically by children-in-household status.

Sexual-minority adults generally have higher adjusted vaccination uptake than heterosexual adults within the same metro-status category, but the evidence is stronger in metro areas. Formal Difference in AMEs estimates show limited evidence of metro/non-metro heterogeneity, except for Hepatitis A, where the sexual-orientation gap is significantly larger in metro areas for both gay/lesbian (0.107) and bisexual (0.079) adults.

Regarding education, findings indicate that sexual minority adults frequently exhibit higher adjusted vaccination probabilities compared to heterosexual adults among both high school/GED and college-or-above cohorts. Nevertheless, most AME differences between education levels (HS vs. College) are not statistically significant. However, bisexual adults show more

pronounced education-related heterogeneity regarding influenza and COVID-19 immunizations. When compared to bisexual adults who have not completed high school, the COVID-19 Difference in AMEs is 0.222 for those with a high school/GED and 0.177 for those with a college-level education or higher. Additionally, the college-and-above AME difference (0.117) for influenza vaccination is also significant.

Race/ethnicity-stratified results show that sexual-minority adults generally have higher adjusted vaccination uptake than heterosexual adults within the same race/ethnicity group. The pattern is most consistent among NH White adults. For example, among gay/lesbian NH White adults, the AMEs are positive and statistically significant for Hepatitis A (0.107), Hepatitis B (0.178), flu (0.116), and COVID-19 (0.135). For bisexual NH White adults, the AMEs are also positive across all four vaccines. However, the Differences in AME results suggest that these gaps are smaller for some racial/ethnic minority groups than for NH White adults, especially for COVID-19 vaccination. For bisexual adults, the COVID-19 AME difference is significantly lower among NH Black adults by 0.111, Hispanic adults by 0.053, and others/NH multiple-race adults by 0.097 relative to NH White adults.

In summary, [Appendix A5](#) suggests that sexual-minority adults generally have higher adjusted vaccination uptake than heterosexual adults within the same demographic or socioeconomic subgroup. However, the magnitude and consistency of these sexual-orientation gaps vary across subgroups. Positive sexual-orientation differences are often more consistent among adults without children, metro residents, more educated adults, and non-Hispanic White adults. The clearest evidence of subgroup heterogeneity appears for hepatitis A by children-in-household status and metro status, and for COVID-19 by marital status, education among bisexual adults, and race/ethnicity. These results suggest that sexual-orientation differences in vaccination uptake are not uniform across demographic and socioeconomic groups and should be interpreted as exploratory evidence of heterogeneity.

5. Discussion

Significant sexual-orientation differences in vaccination uptake remained after adjusting for demographic, socioeconomic, health-access, behavioral, and health-status characteristics. However, these differences were not uniform across vaccines or sexual-orientation subgroups. In the full adjusted model, gay/lesbian adults had substantially higher adjusted probabilities of reporting several vaccinations compared with heterosexual adults. The largest differences were observed in Hepatitis B, shingles, COVID-19, and Hepatitis A vaccination. Relative to heterosexual adults, gay/lesbian adults had higher adjusted probabilities of reporting by 16.4, 12.9, 11.1, and 10.4 percentage points, respectively. These findings are broadly consistent with prior studies showing higher uptake of several adult vaccines among gay/lesbian adults (Srivastav et al., 2019; McNaghten et al., 2022; Park & Kim, 2024). However, the gay/lesbian

HPV estimate was not statistically significant, likely due to the very small sample size and wide confidence interval.

The gender-stratified results also suggest that the stronger gay/lesbian pattern in the full model is driven largely by male respondents. In Table 5, gay/lesbian males had significantly higher adjusted probabilities of reporting most of the vaccination compared with heterosexual males as similar to the main adjusted logistic regression model (Model 2). Among females, however, gay/lesbian adults had significant positive differences only for Hepatitis B, COVID-19, and shingles vaccination compared with heterosexual females. This suggests that gay/lesbian adults' higher vaccination uptake is not simply a general sexual-minority pattern; it is especially pronounced among gay/lesbian males. Consistent with previous research, gay and lesbian adults generally exhibit higher vaccination coverage (Srivastav et al., 2019). This pattern may be related to several factors, including higher levels of educational attainment among gay/lesbian adults (Carpenter et al., 2024), the predominantly male composition in this sample, greater overall confidence in vaccines (McNaghten et al., 2022), and the impact of targeted public health recommendations.

For bisexual adults, the adjusted pattern was more selective. In the full adjusted model, the largest difference was for HPV vaccination, where bisexual adults had an 18.6 percentage-point higher adjusted probability of reporting HPV vaccination than heterosexual adults. Bisexual adults also had higher adjusted probabilities of COVID-19 vaccination, Hepatitis A vaccination, and Hepatitis B vaccination, although the magnitudes were generally smaller than those observed for gay/lesbian adults. In contrast, bisexual adults did not differ significantly from heterosexual adults for tetanus/Td, shingles, or pneumococcal vaccination.

The gender-stratified findings further show that bisexual adults' higher vaccination uptake was concentrated in specific vaccines and gender groups. Among males, bisexual adults had significantly higher adjusted probabilities of HPV, Hepatitis A, Hepatitis B, flu, and COVID-19 vaccination compared with heterosexual males. Among females, bisexual adults had significantly higher adjusted probabilities of HPV, Hepatitis A, and COVID-19 vaccination, but not Hepatitis B, flu, tetanus/Td, shingles, or pneumococcal vaccination. The largest estimates were for HPV vaccination in both the male and female respondents: bisexual males had a 27.5 percentage-point higher adjusted probability, and bisexual females had a 16.9 percentage-point higher adjusted probability of reporting than their same-gender heterosexual reference groups. However, the male HPV estimate should be interpreted cautiously because the HPV-eligible male sample was small and the confidence interval was wide.

Therefore, vaccination patterns among bisexual adults were varied. While they generally showed less consistent adjusted advantages than gay/lesbian adults across most vaccines. Potential contributors to these patterns include the fact that bisexual adults in this study were more frequently female, were younger, were less likely to have health insurance or a usual source of

care, and were more likely to live below the poverty line. These characteristics align with earlier research by Carpenter et al.(2024), Srivastav et al. (2019), and McNaghten et al. (2022). In addition, prior research suggests that gay men may disclose same-sex sexual behavior to primary care providers more frequently than bisexual men (Reiter and Brewer, 2011). Greater disclosure may create more opportunities for providers to recommend vaccines such as Hepatitis A and Hepatitis B when clinically relevant. Higher HPV estimates among bisexual adults and gender-specific bisexual groups may reflect the vaccine’s recommendation history and public-health messaging. HPV vaccination was initially framed heavily around cervical cancer prevention, with early recommendations and marketing focused more strongly on females. Later expansion to males, including approval for males ages 9–26 in 2009, broadened the eligible population and increased attention to prevention of genital warts and anal cancer (Daley et al., 2016, 2017; Markowitz et al., 2014). These results reinforce the importance of analyzing gay/lesbian and bisexual adults separately rather than treating sexual minority adults as a single homogeneous group.

6. Limitation

This study has several limitations. **First**, the analysis is limited by the measurement of sexual orientation in the NHIS. Respondents who answered “something else,” “I don’t know,” or “refused” to the sexual orientation question were excluded from the analytic sample. This exclusion may introduce nonresponse bias and prevent analysis of respondents who may be questioning, still in the process of defining their sexuality, fluid in their identity, or unwilling to select a conventional sexual-orientation label. It also limits the ability to examine broader sexual orientation and gender identity (SOGI) heterogeneity, including transgender and nonbinary respondents, because this study relies primarily on self-reported sexual orientation identity rather than a fuller set of SOGI measures. **Second**, sexual orientation identity may not fully capture sexual minority status. Carpenter et al. (2025) demonstrate that many individuals identify as heterosexual while concurrently reporting some same-sex attraction may be missed when surveys rely only on self-identified sexual orientation. This distinction is important because sexual orientation identity, sexual attraction, and sexual behavior do not always align. Therefore, this study cannot identify respondents who report heterosexual identity but may have same-sex attraction or same-sex behavior. **Third**, even after pooling four years of NHIS data, the number of gay/lesbian and bisexual adults remained small when stratified across covariates or vaccine-specific subpopulations. This reduced statistical power and made some subgroup estimates unstable or imprecise. This issue was more severe for vaccines with limited survey-year availability. Hepatitis A, Hepatitis B, HPV, and tetanus/Td vaccination questions were not asked every year from 2021 to 2024; HPV and Td questions were available only in 2022. As a result, this study could not pool all four years for every vaccine outcome, limiting the ability to stabilize estimates for smaller LGB subgroups. **Fourth**, vaccination outcomes were self-reported and may be affected by recall bias. Respondents may not accurately remember whether they received a vaccine, when they received it, or which vaccine type they received.

Prior validation research suggests that self-reported vaccination status has at least 70% sensitivity for influenza, pneumococcal, tetanus, herpes zoster, and Hepatitis B vaccines and at least 70% specificity for these vaccines, except for tetanus and Hepatitis B (Mac Donald et al., 1999; Mangtani et al., 2007; Rolnick et al., 2013; Willis et al., 2005; Zimmerman et al., 2003). In addition, tetanus estimates may be uncertain because respondents may remember receiving a tetanus shot but not whether it was Td or Tdap. Several NHIS vaccine questions also ask whether the respondent has ever received the vaccine, which captures receipt of at least one dose but does not necessarily indicate completion of a full vaccine series. Therefore, some estimates may reflect partial vaccination rather than complete vaccination. **Fifth**, some vaccine-specific eligibility and risk factors could not be fully measured. For Hepatitis A and Hepatitis B, adult vaccination recommendations apply to adults who are at risk or who seek protection, but NHIS does not collect information on all HAV/HBV risk conditions. The survey also does not provide detailed measures of prevention practices during risky sexual behaviors, limiting further stratification among LGB adults. For shingles and pneumococcal vaccines, this study did not analyze vaccination among immunocompromised adults under age 50 because NHIS lacks sufficient clinical detail to differentiate the severity of immunosuppression. **Sixth**, the NHIS survey weights represent the general adult population rather than the LGB population specifically. Because population-level LGBTQ+ benchmarks remain limited, this study could not apply weights specifically designed to represent LGB adults. In addition, NHIS does not provide unique identifiers across survey years, so it was not possible to confirm whether any respondents appeared in more than one wave. **Seventh**, Sample Adult response rates varied across the study period, from 50.9% in 2021 to 47.7% in 2022, 47.0% in 2023, and 47.9% in 2024. Differences across studies may therefore reflect survey design, survey mode, question wording, weighting approaches, or differential nonresponse by sexual orientation. **Eighth**, unmeasured confounding may remain. Although the models adjusted for a broad set of demographic, socioeconomic, health-access, behavioral, and health-condition covariates, the capstone does not capture all factors that may shape vaccination uptake. In particular, this study could not directly examine trust in health care, stigma, culturally competent care, discrimination in health care settings, provider recommendation, or comfort disclosing sexual orientation to clinicians. These factors may affect vaccine acceptance and access among sexual minority adults and could bias the estimated associations. **Finally**, the study may also be subject to self-selection bias if vaccinated individuals were more likely to participate in the survey. This could lead to higher reported vaccination rates than those in the underlying population.

7. Future Directions

Future research should continue using later NHIS waves to monitor vaccination coverage by sexual orientation and assess whether the patterns observed in this study persist over time. Pooling additional years will be especially important for stabilizing estimates among smaller LGB subgroups and supporting more detailed heterogeneity analyses. Future vaccine uptake

research should also use an intersectional lens by examining how sexual orientation, gender identity, race/ethnicity, gender, age, and socioeconomic position jointly shape vaccination attitudes, access, and behavior. Better sampling strategies and questionnaire design are also needed so that population-based research does not overlook individuals with multiple marginalized identities, including people whose sexual identity and sexual attraction do not align. Future studies should further examine structural and contextual factors that could not be fully assessed in this study, including stigma, discrimination in health care settings, trust in providers, culturally competent care, socioeconomic hardship, state policy environments, and access to affirming clinical services.

The findings also point to several policy and practice implications. Public health programs should develop targeted, age-appropriate vaccination campaigns for LGB adults and other adults at increased risk for vaccine-preventable diseases, particularly as vaccine guidelines expand. Annual campaigns for influenza and COVID-19 provide consistent reminders through pharmacies and public health messaging, while vaccines such as HPV, Hepatitis A, and Hepatitis B are more often administered as multi-dose or one-time adult vaccine series and may receive less routine public attention. This creates missed opportunities for adult vaccination counseling, especially during routine care visits. These vaccines are especially relevant because HPV and Hepatitis B can be sexually transmitted, and Hepatitis A has also been associated with outbreaks among some adult populations. These gaps are also relevant to national prevention goals. Healthy People 2030 aims to reduce HPV infections among young adults aged 20–34 years from 15.1% to 8.7%, acute Hepatitis A to 0.4 cases per 100,000 population, and acute Hepatitis B to 0.1 cases per 100,000 population. However, 2023 surveillance data show that acute Hepatitis A and acute Hepatitis B rates remained above these targets, at approximately 0.5 and 0.7 cases per 100,000 population, respectively. These patterns support continued catch-up vaccination campaigns and stronger adult vaccine counseling for HPV, Hepatitis A, and Hepatitis B among adults who missed the early vaccination window. Provider-based strategies should therefore include routine assessment of adult vaccine eligibility, stronger counseling for Hepatitis A, Hepatitis B, HPV, and other adult vaccines, and expanded vaccination opportunities in LGBTQ+-serving clinics, HIV counseling and testing sites, and other community-based settings. Clinical environments should also help patients feel comfortable discussing sexual orientation, gender identity, and sexual-health risks when clinically relevant by using nondiscrimination statements, inclusive language, and nonjudgmental sexual-health questions.

Improving vaccination equity also requires stronger sexual orientation and gender identity (SOGI) data infrastructure. SOGI measures should be included consistently in national surveys, clinical settings, medicaid applications, electronic health records, claims data, case reporting systems, and vaccination administration systems. Better SOGI data would allow public health agencies to monitor disparities, identify high-coverage groups to understand drivers of vaccine acceptance, and identify lower-coverage groups where hesitancy, access barriers, or discrimination may be more pronounced. At the same time, SOGI data collection must be

implemented carefully, with clear privacy protections, restricted access, and strong safeguards against misuse, especially in contexts where privacy concerns may reduce willingness to disclose sexual orientation or gender identity. Broader nondiscrimination protections in healthcare and public health settings may also support vaccination equity by reducing barriers to care among sexual and gender minority populations.

8. Conclusion

This capstone study provides evidence that adult vaccination uptake varies meaningfully by sexual orientation, vaccine type, and subgroup among U.S. adults. While gay/lesbian and bisexual adults often show higher adjusted uptake for several vaccines, the patterns are not uniform across vaccine outcomes or demographic groups. These findings suggest that sexual minority adults should not be treated as a single homogeneous population in vaccination and health policy research. Continued data collection, more complete sexual orientation and gender identity (SOGI) and sexual-attraction measures, larger pooled samples, intersectional analysis, targeted vaccine communication, provider-based strategies, and affirming clinical environments are needed to better understand and address vaccination differences among sexual minority populations.

References

- Anderson, T. C., Masters, N. B., Guo, A., Shepersky, L., Leidner, A. J., Lee, G. M., Kotton, C. N., Dooling, K. L., & the Advisory Committee on Immunization Practices. (2022). Use of recombinant zoster vaccine in immunocompromised adults aged ≥ 19 years: Recommendations of the Advisory Committee on Immunization Practices—United States, 2022. *Morbidity and Mortality Weekly Report*, 71(3), 80–84. <https://doi.org/10.15585/mmwr.mm7103a2>
- Antecol, H., Jong, A., & Steinberger, M. D. (2008). The sexual orientation wage gap: The role of occupational sorting and human capital. *Industrial and Labor Relations Review*, 61(4), 518–543. <https://doi.org/10.1177/001979390806100405>
- Arrow, K. J. (1963). Uncertainty and the welfare economics of medical care. *The American Economic Review*, 53(5), 941–973.
- Badgett, M. V. L., Carpenter, C. S., & Sansone, D. (2021). LGBTQ economics. *Journal of Economic Perspectives*, 35(2), 141–170. <https://doi.org/10.1257/jep.35.2.141>
- Badgett, M. V. L., Carpenter, C. S., Lee, M. J., & Sansone, D. (2024). A review of the economics of sexual orientation and gender identity. *Journal of Economic Literature*, 62(3), 948–994. <https://doi.org/10.1257/jel.20231668>
- Blanchet Zumofen, M. H., Frimpter, J., & Hansen, S. A. (2023). Impact of influenza and influenza-like illness on work productivity outcomes: A systematic literature review. *Pharmacoeconomics*, 41, 253–273. <https://doi.org/10.1007/s40273-022-01224-9>
- Blewett, L. A., Rivera Drew, J. A., Fenelon, A., King, M. L., Williams, K. C. W., Backman, D., Breton, E., Cooper, G., & Richards, S. (2025). *IPUMS Health Surveys: National Health Interview Survey, Version 8.1* [Data set]. IPUMS. <https://doi.org/10.18128/D071.V8.1>
- Blondeel, K., Say, L., Chou, D., Toskin, I., Khosla, R., Scolaro, E., & Temmerman, M. (2016). Evidence and knowledge gaps on the disease burden in sexual and gender minorities: A review of systematic reviews. *International Journal for Equity in Health*, 15, Article 16. <https://doi.org/10.1186/s12939-016-0304-1>
- Blosnich, J. R., Farmer, G. W., Lee, J. G. L., Silenzio, V. M. B., & Bowen, D. J. (2014). Health inequalities among sexual minority adults: Evidence from ten U.S. states, 2010. *American Journal of Preventive Medicine*, 46(4), 337–349. <https://doi.org/10.1016/j.amepre.2013.11.010>
- Boehmer, U. (2002). Twenty years of public health research: Inclusion of lesbian, gay, bisexual, and transgender populations. *American Journal of Public Health*, 92(7), 1125–1130. <https://doi.org/10.2105/AJPH.92.7.1125>

- Bostwick, W. B., Boyd, C. J., Hughes, T. L., & McCabe, S. E. (2010). Dimensions of sexual orientation and the prevalence of mood and anxiety disorders in the United States. *American Journal of Public Health, 100*(3), 468–475. <https://doi.org/10.2105/AJPH.2008.152942>
- Buchmueller, T., & Carpenter, C. S. (2010). Disparities in health insurance coverage, access, and outcomes for individuals in same-sex versus different-sex relationships, 2000–2007. *American Journal of Public Health, 100*(3), 489–495. <https://doi.org/10.2105/AJPH.2009.160804>
- Carpenter, C. S., Gonzales, G., McKay, T., & Sansone, D. (2020). Effects of the Affordable Care Act dependent coverage mandate on health insurance coverage for individuals in same-sex couples (NBER Working Paper No. 26978). National Bureau of Economic Research. <https://doi.org/10.3386/w26978>
- Carpenter, C. S., & Lawler, E. C. (2019). Direct and spillover effects of middle school vaccination requirements. *American Economic Journal: Economic Policy, 11*(1), 95–125. <https://doi.org/10.1257/pol.20170067>
- Centers for Disease Control and Prevention. (2022). *Adult vaccination coverage, 2022*. U.S. Department of Health and Human Services. <https://www.cdc.gov/adultvaxview/publications-resources/adult-vaccination-coverage-2022.html>
- Centers for Disease Control and Prevention. (2024, June 3). *Primary prevention methods*. In *Sexually transmitted infections treatment guidelines, 2021*. U.S. Department of Health and Human Services. <https://www.cdc.gov/std/treatment-guidelines/clinical-primary.htm>
- Centers for Disease Control and Prevention. (2025, July 2). *Adult immunization schedule by age: Recommendations for ages 19 years or older, United States, 2025*. U.S. Department of Health and Human Services. <https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-age.html>
- Cochran, S. D., Björkenstam, C., & Mays, V. M. (2016). Sexual orientation and all-cause mortality among US adults aged 18 to 59 years, 2001–2011. *American Journal of Public Health, 106*(5), 918–920. <https://doi.org/10.2105/AJPH.2016.303052>
- Conron, K. J., Mimiaga, M. J., & Landers, S. J. (2010). A population-based study of sexual orientation identity and gender differences in adult health. *American Journal of Public Health, 100*(10), 1953–1960. <https://doi.org/10.2105/AJPH.2009.174169>
- Cutler, D. M., & Lleras-Muney, A. (2010). Understanding differences in health behaviors by education. *Journal of Health Economics, 29*(1), 1–28. <https://doi.org/10.1016/j.jhealeco.2009.10.003>

Dahlhamer, J. M., Galinsky, A. M., Joestl, S. S., & Ward, B. W. (2016). Barriers to health care among adults identifying as sexual minorities: A US national study. *American Journal of Public Health, 106*(6), 1116–1122.

Daley, E. M., Vamos, C. A., Thompson, E. L., Zimet, G. D., Rosberger, Z., Merrell, L., et al. (2017). The feminization of HPV: How science, politics, economics and gender norms shaped U.S. HPV vaccine implementation. *Papillomavirus Research, 3*, 142–148.

Daley, E. M., Vamos, C. A., Zimet, G. D., Rosberger, Z., Thompson, E. L., & Merrell, L. (2016). The feminization of HPV: Reversing gender biases in US human papillomavirus vaccine policy. *American Journal of Public Health, 106*, 983–984.

Drydakis, N. (2019). Sexual orientation and labor market outcomes. *IZA World of Labor, 111*.
<https://doi.org/10.15185/izawol.111.v2>

Ellis, R. P., & Manning, W. G. (2007). Optimal health insurance for prevention and treatment. *Journal of Health Economics, 26*(6), 1128–1150. <https://doi.org/10.1016/j.jhealeco.2007.09.002>

Epstein, D., Jiménez-Rubio, D., Smith, P. C., & Suhrcke, M. (2009). Social determinants of health: An economic perspective. *Health Economics, 18*(5), 495–502.
<https://doi.org/10.1002/hec.1490>

Freedman, S. M., Sacks, D. W., Simon, K. I., & Wing, C. (2023). *Direct and indirect effects of vaccines: Evidence from COVID-19* (NBER Working Paper No. 30550). National Bureau of Economic Research.

Gonzales, G., & Blewett, L. A. (2014). National and state-specific health insurance disparities for adults in same-sex relationships. *American Journal of Public Health, 104*(2), e95–e105.
<https://doi.org/10.2105/AJPH.2013.301577>

Gonzales, G., & Henning-Smith, C. (2017). Health disparities by sexual orientation: Results and implications from the Behavioral Risk Factor Surveillance System. *Journal of Community Health, 42*, 1163–1172. <https://doi.org/10.1007/s10900-017-0366-z>

Gonzales, G., Przedworski, J., & Henning-Smith, C. (2016). Comparison of health and health risk factors between lesbian, gay, and bisexual adults and heterosexual adults in the United States: Results from the National Health Interview Survey. *JAMA Internal Medicine, 176*(9), 1344–1351. <https://doi.org/10.1001/jamainternmed.2016.3432>

Gorman, B. K., Denney, J. T., Dowdy, H., & Medeiros, R. A. (2015). A new piece of the puzzle: Sexual orientation, gender, and physical health status. *Demography, 52*(4), 1357–1382.
<https://doi.org/10.1007/s13524-015-0406-1>

- Granade, C. J., Lindley, M. C., Jatlaoui, T., Asif, A. F., & Jones-Jack, N. (2022). Racial and ethnic disparities in adult vaccination: A review of the state of evidence. *Health Equity*, 6(1), 206–223. <https://doi.org/10.1089/heq.2021.0177>
- Hatzenbuehler, M. L., McLaughlin, K. A., & Nolen-Hoeksema, S. (2008). Emotion regulation and internalizing symptoms in a longitudinal study of sexual minority and heterosexual adolescents. *Journal of Child Psychology and Psychiatry*, 49(12), 1270–1278. <https://doi.org/10.1111/j.1469-7610.2008.01924.x>
- Healthy People 2030. (n.d.). *Vaccination*. U.S. Department of Health and Human Services, Office of Disease Prevention and Health Promotion. <https://odphp.health.gov/healthypeople/objectives-and-data/browse-objectives/vaccination>.
- Heck, J. E., Sell, R. L., & Gorin, S. S. (2006). Health care access among individuals involved in same-sex relationships. *American Journal of Public Health*, 96(6), 1111–1118. <https://doi.org/10.2105/AJPH.2005.062661>
- Heer, E., Peters, C., Knight, R., Yang, L., & Heitman, S. J. (2023). Participation, barriers, and facilitators of cancer screening among LGBTQ+ populations: A review of the literature. *Preventive Medicine*, 170, Article 107478. <https://doi.org/10.1016/j.ypmed.2023.107478>
- Hsieh, N. (2024). Unpacking intersectional inequities in flu vaccination by sexuality, gender, and race-ethnicity in the United States. *Journal of Health and Social Behavior*, 65(1), 38–59. <https://doi.org/10.1177/00221465231199276>
- Immunize.org. (2025, October 15). *Vaccinations for men who have sex with men* [Fact sheet]. <https://www.immunize.org/wp-content/uploads/catg.d/p4046.pdf>
- Kini, A., Morgan, R., Kuo, H., Shea, P., Shapiro, J., Leng, S. X., Pekosz, A., & Klein, S. L. (2022). Differences and disparities in seasonal influenza vaccine, acceptance, adverse reactions, and coverage by age, sex, gender, and race. *Vaccine*, 40(11), 1643–1654. <https://doi.org/10.1016/j.vaccine.2021.04.013>
- Kirson, N., Swallow, E., Lu, J., Mesa-Frias, M., Bookhart, B., Maynard, J., Shivdasani, Y., & Lefebvre, P. (2022). The societal economic value of COVID-19 vaccines in the United States. *Journal of Medical Economics*, 25(1), 119–128. <https://doi.org/10.1080/13696998.2022.2026118>
- Kobayashi, M., Leidner, A. J., Gierke, R., Britton, A., Childs, L., Leidner, L. R., Campos-Outcalt, D., Morgan, R. L., Lee, G. M., Talbot, H. K., & Kobayashi, M. (2025). Expanded recommendations for use of pneumococcal conjugate vaccines among adults aged ≥50 years: Recommendations of the Advisory Committee on Immunization Practices—United States, 2024. *Morbidity and Mortality Weekly Report*, 74(1), 1–8. <https://doi.org/10.15585/mmwr.mm7401a1>

- Krause, K. D., D'Avanzo, P. A., Karr, A. G., Rhem, C., & Halkitis, P. N. (2024). Vaccination uptake in LGBTQ adults in two US states: Findings from the QVax study. *Vaccine*, 42, Article 126320. <https://doi.org/10.1016/j.vaccine.2024.126320>
- Lleras-Muney, A. (2005). The relationship between education and adult mortality in the United States. *The Review of Economic Studies*, 72(1), 189–221. <https://doi.org/10.1111/0034-6527.00329>
- Lu, P.-J., O'Halloran, A., Williams, W. W., Lindley, M. C., Farrall, S., & Bridges, C. B. (2015). Racial and ethnic disparities in vaccination coverage among adult populations in the U.S. *American Journal of Preventive Medicine*, 49(6 Suppl 4), S412–S425. <https://doi.org/10.1016/j.amepre.2015.03.005>
- Mac Donald, R., Baken, L., Nelson, A., & Nichol, K. L. (1999). Validation of self-report of influenza and pneumococcal vaccination status in elderly outpatients. *American Journal of Preventive Medicine*, 16(3), 173–177.
- Mangtani, P., Shah, A., & Roberts, J. A. (2007). Validation of influenza and pneumococcal vaccine status in adults based on self-report. *Epidemiology and Infection*, 135(1), 139–143. <https://doi.org/10.1017/S0950268806006479>
- Markowitz, L. E., Dunne, E. F., Saraiya, M., Chesson, H. W., Curtis, C. R., Gee, J., et al. (2014). Human papillomavirus vaccination: Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recommendations and Reports*, 63, 1–30.
- McNaghten, A. D., Brewer, N. T., Hung, M.-C., Lu, P.-J., Daskalakis, D., Abad, N., Kriss, J., Black, C., Wilhelm, E., Lee, J. T., Gundlapalli, A., Cleveland, J., Elam-Evans, L., Bonner, K., & Singleton, J. (2022). COVID-19 vaccination coverage and vaccine confidence by sexual orientation and gender identity—United States, August 29–October 30, 2021. *Morbidity and Mortality Weekly Report*, 71(5), 171–176. <https://doi.org/10.15585/mmwr.mm7105a3>
- Meites, E., Szilagyi, P. G., Chesson, H. W., Unger, E. R., Romero, J. R., & Markowitz, L. E. (2019). Human papillomavirus vaccination for adults: Updated recommendations of the Advisory Committee on Immunization Practices. *Morbidity and Mortality Weekly Report*, 68(32), 698–702. <https://www.cdc.gov/mmwr/volumes/68/wr/mm6832a3.htm>
- Meites, E., Wilkin, T. J., & Markowitz, L. E. (2022). Review of human papillomavirus (HPV) burden and HPV vaccination for gay, bisexual, and other men who have sex with men and transgender women in the United States. *Human Vaccines & Immunotherapeutics*, 18(1), 2016007. <https://doi.org/10.1080/21645515.2021.2016007>
- Meyer, I. H. (1995). Minority stress and mental health in gay men. *Journal of Health and Social Behavior*, 36(1), 38–56.

Nguyen, K. H., Levengood, T. W., Gordon, A. R., Menard, E., Allen, A. M., & Gonzales, G. (2024). Inequities in self-reported social risk factors by sexual orientation and gender identity. *JAMA Health Forum*, 5(9), Article e243176. <https://doi.org/10.1001/jamahealthforum.2024.3176>

National Institute for Health and Care Excellence. (2022). *Increasing uptake of hepatitis A, hepatitis B and human papillomavirus (HPV) vaccinations in gay, bisexual and other men who have sex with men: Reducing sexually transmitted infections (STIs): Evidence review F* (NICE Guideline No. 221). NCBI Bookshelf. <https://www.ncbi.nlm.nih.gov/books/NBK589711/>

Office of Disease Prevention and Health Promotion. (n.d.). *LGBT*. U.S. Department of Health and Human Services. <https://odphp.health.gov/healthypeople/objectives-and-data/browse-objectives/lgbt>

Office of Disease Prevention and Health Promotion. (n.d.). *Reduce infections of HPV types prevented by the vaccine in young adults — IID-07 data*. Healthy People 2030. Retrieved July 4, 2026, from <https://odphp.health.gov/healthypeople/objectives-and-data/browse-objectives/infectious-disease/reduce-infections-hpv-types-prevented-vaccine-young-adults-iid-07/data>

Office of Disease Prevention and Health Promotion. (n.d.). *Reduce the rate of hepatitis A — IID-10*. Healthy People 2030. Retrieved July 4, 2026, from <https://odphp.health.gov/healthypeople/objectives-and-data/browse-objectives/infectious-disease/reduce-rate-hepatitis-iid-10>

Office of Disease Prevention and Health Promotion. (n.d.). *Reduce the rate of acute hepatitis B — IID-11 data*. Healthy People 2030. Retrieved July 4, 2026, from <https://odphp.health.gov/healthypeople/objectives-and-data/browse-objectives/infectious-disease/reduce-rate-acute-hepatitis-b-iid-11/data>

Ozawa, S., Portnoy, A., Getaneh, H., Clark, S., Knoll, M., Bishai, D., Yang, H. K., & Patwardhan, P. D. (2016). Modeling the economic burden of adult vaccine-preventable diseases in the United States. *Health Affairs*, 35(11), 2124–2132. <https://doi.org/10.1377/hlthaff.2016.0462>

Padula, W. V., Malaviya, S., Reid, N. M., Cohen, B. G., Chingcuanco, F., Ballreich, J., Tierce, J., & Alexander, G. C. (2021). Economic value of vaccines to address the COVID-19 pandemic: A U.S. cost-effectiveness and budget impact analysis. *Journal of Medical Economics*, 24(1), 1060–1069. <https://doi.org/10.1080/13696998.2021.1965732>

Park, J., & Kim, B. (2024). Heterogeneous associations between pandemic-induced socioeconomic hardships and COVID-19 vaccine uptake by sexual orientation and gender

identity: A nationally representative analysis in the United States. *Vaccines*, 12(11), Article 1277. <https://doi.org/10.3390/vaccines12111277>

Patterson, J. G., Jabson, J. M., & Bowen, D. J. (2017). Measuring sexual and gender minority populations in health surveillance. *LGBT Health*, 4(2), 82–105. <https://doi.org/10.1089/lgbt.2016.0026>

Peña, J. M., Schwartz, M. R., Hernandez-Vallant, A., & Sanchez, G. R. (2023). Social and structural determinants of COVID-19 vaccine uptake among racial and ethnic groups. *Journal of Behavioral Medicine*, 46, 129–139. <https://doi.org/10.1007/s10865-023-00393-y>

Pharr, J. R., Kachen, A., & Cross, C. (2019). Health disparities among sexual gender minority women in the United States: A population-based study. *Journal of Community Health*, 44, 721–728. <https://doi.org/10.1007/s10900-019-00631-y>

Polonijo, A. N., & Vogelsang, E. M. (2023). Sexual orientation and gender identity differences in influenza, shingles, and pneumococcal vaccination among U.S. older adults. *LGBT Health*, 10(4), 316–324. <https://doi.org/10.1089/lgbt.2022.0191>

Ponce, N. A., Cochran, S. D., Pizer, J. C., & Mays, V. M. (2010). The effects of unequal access to health insurance for same-sex couples in California. *Health Affairs*, 29(8), 1539–1548. <https://doi.org/10.1377/hlthaff.2009.0583>

Rangel, M. C., Shoenbach, V. J., Weigle, K. A., Hogan, V. K., Strauss, R. P., & Bangdiwala, S. I. (2005). Racial and ethnic disparities in influenza vaccination among elderly adults. *Journal of General Internal Medicine*, 20(5), 426–431. <https://doi.org/10.1111/j.1525-1497.2005.0097.x>

Reiter, P. L., & Brewer, N. T. (2011). Hepatitis B vaccination among a national sample of gay and bisexual men. *Sexually Transmitted Diseases*, 38(3), 235–238. <https://doi.org/10.1097/OLQ.0b013e3181f422bb>

Rolnick, S. J., Parker, E. D., Nordin, J. D., Hedblom, B. D., Wei, F., Kerby, T., et al. (2013). Self-report compared to electronic medical record across eight adult vaccines: Do results vary by demographic factors? *Vaccine*, 31(37), 3928–3935. <https://doi.org/10.1016/j.vaccine.2013.06.041>

Sabia, J. J. (2014). Sexual orientation and wages in young adulthood: New evidence from Add Health. *ILR Review*, 67(1), 239–267. <https://doi.org/10.1177/001979391406700109>

Sandul, A. L., Rapposelli, K., Nyendak, M., & Kim, M. (2024). Updated recommendation for universal hepatitis B vaccination in adults aged 19–59 years—United States, 2024. *Morbidity and Mortality Weekly Report*, 73(48), 1106. <https://doi.org/10.15585/mmwr.mm7348a3>

- Silva, J. F., & Costa, G. M. C. (2020). Health care of sexual and gender minorities: An integrative literature review. *Revista Brasileira de Enfermagem*, 73(Suppl. 6), Article e20190192. <https://doi.org/10.1590/0034-7167-2019-0192>
- Srivastav, A., O'Halloran, A., Lu, P.-J., Williams, W. W., & Hutchins, S. S. (2019). Vaccination differences among U.S. adults by their self-identified sexual orientation, National Health Interview Survey, 2013–2015. *PLOS ONE*, 14(3), Article e0213431. <https://doi.org/10.1371/journal.pone.0213431>
- U.S. Department of Health and Human Services. (2020). *Viral hepatitis national strategic plan for the United States: A roadmap to elimination (2021–2025)*. <https://www.hhs.gov/sites/default/files/Viral-Hepatitis-National-Strategic-Plan-2021-2025.pdf>
- U.S. Department of Health and Human Services, Office of Disease Prevention and Health Promotion. (n.d.). *Healthy People 2030 framework*. <https://odphp.health.gov/healthypeople/about/healthy-people-2030-framework>
- White, C. (2019). *Measuring social and externality benefits of influenza vaccination* (IZA Discussion Paper No. 12525). IZA Institute of Labor Economics.
- Willis, B. C., Ndiaye, S. M., Hopkins, D. P., Shefer, A., & Task Force on Community Preventive Services. (2005). Improving influenza, pneumococcal polysaccharide, and hepatitis B vaccination coverage among adults aged <65 years at high risk: A report on recommendations of the Task Force on Community Preventive Services. *MMWR Recommendations and Reports*, 54(RR-5), 1–11.
- Xu, J., Narla, S. S., Davoudpour, S., Ruprecht, M. M., Curtis, M. G., & Phillips, G., II. (2024). COVID-19 testing and vaccination uptake among youth and young adults: Disparities by age, race/ethnicity, sexual orientation, and gender identity. *American Journal of Infection Control*, 52(3), 312–319. <https://doi.org/10.1016/j.ajic.2023.09.010>
- Zimmerman, R. K., Raymund, M., Janosky, J. E., Nowalk, M. P., & Fine, M. J. (2003). Sensitivity and specificity of patient self-report of influenza and pneumococcal polysaccharide vaccinations among elderly outpatients in diverse patient care strata. *Vaccine*, 21(13–14), 1486–1491.

Appendices

Appendix A1: Adjusted Linear Probability Model (LPM) of Vaccination Uptake by Sexual Orientation

	HPV (19-26)	Hepatitis A (19+)	Hepatitis B (19-59)	Flu (19+)	Tetanus (Td) (19+)	COVID-19 (19+)	Shingles (50+)	Pneumonia (50+)
	AME SE (95% CI)	AME SE (95% CI)	AME SE (95% CI)	AME SE (95% CI)	AME SE (95% CI)	AME SE (95% CI)	AME SE (95% CI)	AME SE (95% CI)
Gay or Lesbian	0.042 (0.072) [-0.099, 0.183]	0.114*** (0.019) [0.077, 0.150]	0.168*** (0.023) [0.122, 0.214]	0.095*** (0.013) [0.069, 0.120]	0.038 (0.024) [-0.011, 0.086]	0.113*** (0.009) [0.095, 0.132]	0.139*** (0.018) [0.104, 0.174]	0.094*** (0.017) [0.060, 0.127]
Bisexual	0.193*** (0.042) [0.111, 0.274]	0.090*** (0.018) [0.054, 0.127]	0.045* (0.024) [-0.002, 0.092]	0.034*** (0.012) [0.011, 0.057]	0.028 (0.026) [-0.023, 0.080]	0.114*** (0.011) [0.092, 0.136]	0.046 (0.030) [-0.012, 0.105]	0.001 (0.031) [-0.060, 0.062]

Appendix A2: Adjusted Logistic Regression Analysis of Vaccination Uptake by Combined Sexual Minority Group

Sexual Minority	0.145*** (0.037) [0.071, 0.218]	0.090*** (0.012) [0.066, 0.114]	0.102*** (0.018) [0.068, 0.137]	0.061*** (0.008) [0.045, 0.078]	0.032* (0.019) [-0.004, 0.069]	0.099*** (0.006) [0.087, 0.112]	0.109*** (0.015) [0.080, 0.137]	0.063*** (0.014) [0.036, 0.090]
--------------------	--	--	--	--	---	--	--	--

Appendix A3: Adjusted Logistic Regression Analysis of Vaccination Uptake with Survey Year Fixed Effects

Gay or Lesbian	--	0.104*** (0.018) [0.070, 0.139]	0.164*** (0.023) [0.120, 0.209]	0.092*** (0.012) [0.067, 0.116]	--	0.111*** (0.009) [0.094, 0.129]	0.131*** (0.017) [0.099, 0.164]	0.084*** (0.015) [0.053, 0.114]
Bisexual	--	0.076*** (0.016) [0.044, 0.108]	0.043* (0.023) [-0.003, 0.089]	0.038*** (0.011) [0.016, 0.061]	--	0.093*** (0.008) [0.076, 0.109]	0.046 (0.028) [-0.009, 0.101]	0.001 (0.026) [-0.051, 0.052]
Analytic Subpopulation N	1,758	50,389	24,466	107,625	23,284	100,846	61,505	60,914

-- indicates that the vaccine outcome was not included because it was available in only one survey year for this analytic sample.

Notes:

1. Heterosexual respondents serve as the reference category for all models presented in these appendices.
2. Except for the HPV and Tetanus vaccine data in Appendix A3, the specified analytic subpopulation size is consistent across all logistic regression models in these appendices.

Appendix A5: Heterogeneity in Sexual-Orientation Differences in Vaccination Uptake by Demographic and Socioeconomic Subgroups

Vaccines ->									
Sexual Orientation ↓	Subgroup Categories ↓	Hepatitis A (19+)		Hepatitis B (19-59)		Flu (19+)		COVID-19 (19+)	
		AME SE (95% CI)	Difference in AMEs SE (95% CI)	AME SE (95% CI)	Difference in AMEs SE (95% CI)	AME SE (95% CI)	Difference in AMEs SE (95% CI)	AME SE (95% CI)	Difference in AMEs SE (95% CI)
Marital status									
Gay or Lesbian	Married	0.114*** (0.033) [0.050,0.178]	0.011 (0.038) [-0.063,0.086]	0.131*** (0.039) [0.056,0.207]	-0.051 (0.044) [-0.137,0.035]	0.131*** (0.022) [0.087,0.174]	0.037 (0.026) [-0.013,0.087]	0.078*** (0.016) [0.046,0.109]	-0.064*** (0.020) [-0.102,-0.026]
	Others	0.103*** (0.020) [0.063,0.143]		0.182*** (0.026) [0.132,0.233]		0.093*** (0.014) [0.065,0.122]		0.142*** (0.012) [0.119,0.165]	
Bisexual	Married	0.107*** (0.032) [0.044,0.171]	0.036 (0.036) [-0.035,0.107]	0.062 (0.040) [-0.016,0.140]	0.024 (0.050) [-0.074,0.122]	0.046** (0.020) [0.006,0.086]	0.005 (0.026) [-0.046,0.056]	0.079*** (0.013) [0.053,0.104]	-0.032** (0.016) [-0.063,-0.001]
	Others	0.071*** (0.018) [0.035,0.107]		0.038 (0.029) [-0.019,0.095]		0.041*** (0.014) [0.014,0.068]		0.111*** (0.011) [0.090,0.132]	
Children in the household									
Gay or Lesbian	Has Kids	-0.020 (0.050) [-0.119,0.079]	-0.146*** (0.052) [-0.249,-0.043]	0.113* (0.061) [-0.007,0.233]	-0.078 (0.065) [-0.206,0.049]	0.050 (0.037) [-0.023,0.123]	-0.048 (0.038) [-0.123,0.027]	0.046 (0.033) [-0.019,0.110]	-0.060* (0.033) [-0.125,0.006]
	No Kids	0.126*** (0.018) [0.091,0.161]		0.191*** (0.024) [0.145,0.238]		0.098*** (0.013) [0.074,0.123]		0.105*** (0.008) [0.089,0.121]	
Bisexual	Has Kids	0.113*** (0.035) [0.044,0.182]	0.042 (0.040) [-0.037,0.120]	0.056 (0.043) [-0.028,0.140]	0.007 (0.049) [-0.090,0.103]	0.030 (0.024) [-0.017,0.077]	-0.009 (0.027) [-0.062,0.043]	0.069*** (0.019) [0.031,0.106]	-0.022 (0.020) [-0.061,0.016]
	No Kids	0.071*** (0.018) [0.035,0.107]		0.049* (0.027) [-0.004,0.102]		0.039*** (0.013) [0.015,0.064]		0.091*** (0.008) [0.075,0.108]	
Urban-rural status									
Gay or Lesbian	Metro	0.115*** (0.019) [0.078,0.151]	0.107** (0.048) [0.014,0.201]	0.167*** (0.024) [0.121,0.214]	0.035 (0.079) [-0.120,0.190]	0.092*** (0.013) [0.066,0.117]	0.026 (0.041) [-0.055,0.107]	0.103*** (0.009) [0.085,0.121]	-0.035 (0.033) [-0.099,0.030]
	Non-Metro	0.007 (0.044) [-0.079,0.094]		0.132* (0.075) [-0.016,0.281]		0.066* (0.039) [-0.011,0.143]		0.138*** (0.032) [0.076,0.199]	
Bisexual	Metro	0.089*** (0.018) [0.053,0.124]	0.079** (0.036) [0.009,0.149]	0.041 (0.025) [-0.008,0.089]	-0.019 (0.075) [-0.166,0.128]	0.033*** (0.012) [0.010,0.057]	-0.004 (0.036) [-0.075,0.068]	0.084*** (0.009) [0.067,0.101]	-0.038 (0.028) [-0.093,0.018]

Vaccines ->									
Sexual Orientation ↓	Subgroup Categories ↓	Hepatitis A (19+)		Hepatitis B (19-59)		Flu (19+)		COVID-19 (19+)	
		AME SE (95% CI)	Difference in AMEs SE (95% CI)	AME SE (95% CI)	Difference in AMEs SE (95% CI)	AME SE (95% CI)	Difference in AMEs SE (95% CI)	AME SE (95% CI)	Difference in AMEs SE (95% CI)
	Non-Metro	0.009 (0.031) [-0.052,0.070]		0.059 (0.071) [-0.080,0.199]		0.037 (0.035) [-0.031,0.105]		0.121*** (0.027) [0.068,0.174]	
Education									
Gay or Lesbian	Less than HS	0.059 (0.102) [-0.141,0.259]	--	0.159 (0.152) [-0.140,0.458]	--	-0.003 (0.079) [-0.158,0.152]	--	0.043 (0.063) [-0.080,0.166]	--
	HS & GED	0.117*** (0.031) [0.057,0.178]	0.058 (0.106) [-0.150,0.267]	0.198*** (0.039) [0.122,0.274]	0.039 (0.157) [-0.270,0.347]	0.102*** (0.021) [0.061,0.144]	0.105 (0.080) [-0.051,0.262]	0.135*** (0.017) [0.101,0.168]	0.092 (0.064) [-0.034,0.217]
	College & Above	0.104*** (0.022) [0.061,0.147]	0.045 (0.103) [-0.157,0.248]	0.146*** (0.027) [0.093,0.199]	-0.013 (0.155) [-0.317,0.291]	0.090*** (0.015) [0.061,0.119]	0.093 (0.079) [-0.062,0.249]	0.087*** (0.008) [0.071,0.102]	0.044 (0.063) [-0.080,0.167]
Bisexual	Less than HS	0.091 (0.066) [-0.039,0.221]	--	-0.013 (0.087) [-0.184,0.157]	--	-0.033 (0.055) [-0.140,0.074]	--	-0.097* (0.055) [-0.206,0.012]	--
	HS & GED	0.080*** (0.024) [0.033,0.126]	-0.011 (0.070) [-0.148,0.126]	0.058 (0.036) [-0.013,0.129]	0.071 (0.093) [-0.111,0.254]	-0.003 (0.018) [-0.039,0.034]	0.031 (0.057) [-0.082,0.143]	0.125*** (0.015) [0.097,0.154]	0.222*** (0.057) [0.110,0.334]
	College & Above	0.074*** (0.023) [0.029,0.119]	-0.017 (0.071) [-0.156,0.122]	0.033 (0.032) [-0.030,0.096]	0.046 (0.094) [-0.137,0.230]	0.084*** (0.015) [0.054,0.114]	0.117** (0.057) [0.006,0.228]	0.080*** (0.007) [0.066,0.094]	0.177*** (0.056) [0.068,0.287]
Race/ethnicity									
Gay or Lesbian	NH White	0.107*** (0.021) [0.065,0.148]	--	0.178*** (0.027) [0.124,0.231]	--	0.116*** (0.015) [0.087,0.144]	--	0.135*** (0.010) [0.116,0.153]	--
	NH Black	0.066 (0.054) [-0.039,0.171]	-0.041 (0.057) [-0.153,0.072]	0.188*** (0.072) [0.046,0.330]	0.011 (0.076) [-0.138,0.159]	0.034 (0.037) [-0.039,0.106]	-0.082** (0.040) [-0.160,-0.004]	0.081*** (0.031) [0.019,0.142]	-0.054 (0.033) [-0.118,0.011]
	Hispanic	0.065 (0.043) [-0.019,0.148]	-0.042 (0.047) [-0.134,0.050]	0.113* (0.061) [-0.006,0.232]	-0.065 (0.067) [-0.196,0.066]	0.055* (0.029) [-0.003,0.112]	-0.061* (0.031) [-0.123,0.001]	0.054** (0.026) [0.002,0.105]	-0.081*** (0.028) [-0.135,-0.027]
	Others NH Multiple Races	0.225*** (0.059) [0.109,0.341]	0.118* (0.062) [-0.003,0.239]	0.130** (0.058) [0.016,0.244]	-0.048 (0.063) [-0.171,0.076]	0.042 (0.042) [-0.041,0.125]	-0.074* (0.044) [-0.160,0.013]	0.055* (0.028) [-0.000,0.111]	-0.079*** (0.030) [-0.138,-0.020]

Vaccines ->									
Sexual Orientation ↓	Subgroup Categories ↓	Hepatitis A (19+)		Hepatitis B (19-59)		Flu (19+)		COVID-19 (19+)	
		AME SE (95% CI)	Difference in AMEs SE (95% CI)	AME SE (95% CI)	Difference in AMEs SE (95% CI)	AME SE (95% CI)	Difference in AMEs SE (95% CI)	AME SE (95% CI)	Difference in AMEs SE (95% CI)
Bisexual	NH White	0.080*** (0.020) [0.041,0.119]	--	0.053* (0.028) [-0.003,0.109]	--	0.035*** (0.014) [0.009,0.062]	--	0.116*** (0.009) [0.098,0.133]	--
	NH Black	0.061 (0.058) [-0.052,0.175]	-0.019 (0.061) [-0.138,0.100]	0.078 (0.077) [-0.072,0.229]	0.025 (0.082) [-0.136,0.187]	-0.008 (0.037) [-0.080,0.065]	-0.043 (0.039) [-0.119,0.033]	0.004 (0.033) [-0.059,0.068]	-0.111*** (0.033) [-0.176,-0.046]
	Hispanic	0.028 (0.042) [-0.054,0.110]	-0.052 (0.047) [-0.144,0.039]	-0.073 (0.051) [-0.173,0.027]	-0.126** (0.056) [-0.236,-0.016]	0.083*** (0.031) [0.022,0.144]	0.047 (0.034) [-0.019,0.114]	0.063*** (0.023) [0.018,0.108]	-0.053** (0.024) [-0.099,-0.006]
	Others NH Multiple Races	0.173*** (0.057) [0.061,0.285]	0.093 (0.061) [-0.026,0.212]	0.099 (0.073) [-0.045,0.242]	0.046 (0.079) [-0.110,0.201]	0.010 (0.038) [-0.063,0.084]	-0.025 (0.040) [-0.104,0.054]	0.019 (0.024) [-0.028,0.065]	-0.097*** (0.025) [-0.147,-0.047]
Sub-group Sample Size N		50,389		24,466		107,625		100,846	

Notes:

1. Within each subgroup category, heterosexual adults are the reference group.
2. Married includes respondents who were married with spouse present, married with spouse absent, or married with spouse in household unknown. Others include NIU, separated, divorced, widowed, living with partner, never married, and unknown marital status.
3. Has Kids indicates 1 or more kids younger than 18 in the household.
4. Metro includes large central, large fringe, and medium/small metro counties; Non-metro includes nonmetropolitan counties.
5. For binary subgroup comparisons, the Difference in AMEs is Married - Others, Has Kids - No Kids, or Metro - Non-Metro. For education, differences are relative to Less than HS. For race/ethnicity, differences are relative to the NH White population.
6. * p<0.10, ** p<0.05, *** p<0.01.